EP1225909A2 - Facteur de croissance des fibroblastes 5 (fgf-5) dans un antigene de leucocyte t associe aux tumeurs - Google Patents

Facteur de croissance des fibroblastes 5 (fgf-5) dans un antigene de leucocyte t associe aux tumeurs

Info

Publication number
EP1225909A2
EP1225909A2 EP00968465A EP00968465A EP1225909A2 EP 1225909 A2 EP1225909 A2 EP 1225909A2 EP 00968465 A EP00968465 A EP 00968465A EP 00968465 A EP00968465 A EP 00968465A EP 1225909 A2 EP1225909 A2 EP 1225909A2
Authority
EP
European Patent Office
Prior art keywords
fgf
cell
expression
immune response
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00968465A
Other languages
German (de)
English (en)
Inventor
Ken-Ichi Hanada
James C. Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of EP1225909A2 publication Critical patent/EP1225909A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46443—Growth factors
    • A61K39/464432—Fibroblast growth factors [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factors [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Definitions

  • FGF-5 (initially termed FGF-3) is an oncogene-encoded glycoprotein bearing mitogenic activity for fibroblasts and endothelial cells. FGF-5 was previously isolated by transfecting a bladder carcinoma DNA into NIH-3T3 cells (Zhan et al. , Mol Cell Biol. 8:3487-95, 1988 and corresponding U.S. Patent Nos. 5,155,217 (referred to herein as the '217 patent) and 5,238,916 (referred to herein as the '916 patent)). Both the nucleotide and protein sequences were submitted to GenBank under Accession Nos. NM_004464 and NP 004455 in 1990, which are incorporated by reference, as are the '217 and '916 patents.
  • FGF-5 is expressed in RCC (Yoshimura et al. , Cancer Lett. 103:91-7, 1996), as well as cancers of the bladder, liver and endometrium (Zhan et al. , Mol Cell Biol. 8:3487-95, 1988; the '916 and '217 patents; Yoshimura et al. , Cancer Lett. 103:91-7, 1996), pancreas (Kornmann et al. , Oncogene. 15:1417-24, 1997), gastric and esophageal adenocarcinomas (Altorki et al. , Cancer,
  • pancreatic tissue Kernmann et al. , Oncogene, 15: 1417- 24, 1997) human fibroblasts (Werner et al., Oncogene. 6:2137-44, 1991; Albino et al. , 1991), skeletal muscle (Hannon et al. , J. Cell Biol. 132: 1151-9, 1996 and Hughes et al. , Neuron, 10:369- 77, 1993); and adult neurotrophic cells (Goldfarb et al. , Ann N Y Acad Sci. 638:38-52, 1991 ; Kitaoka et al. , Invest. Ophthalmol. Vis. Sci. 35:3189-98, 1994).
  • Renal cell carcinoma although not a common malignancy, accounts for 3% of all adult cancers.
  • Conventional therapies involving the systemic administration of both interleukin-2 (IL-2) and interferon ⁇ (IFN- ⁇ ) result in the long-term remission in less than 20% of patients with metastatic RCC.
  • IL-2 interleukin-2
  • IFN- ⁇ interferon ⁇
  • Osband U.S. Patent No. 5,192,537 discloses a method for treating RCC by in vitro incubation of a patient's T-cells with a tumor extract. The activated T-cells are then infused into the patient to reduce or eliminate the tumor burden. Cimetidine is concurrently administered to inhibit the patient's suppressor cells, and augment the anti-tumor response.
  • the '217 and the '916 patents demonstrate that FGF-5 is expressed in bladder, liver, and endometrial cancers.
  • these patents disclose a method for treating FGF-5 expressing cancers by the administration of antibodies which recognize FGF-5. Such antibodies are also disclosed as diagnostic agents.
  • FGF-5 expression in RCC there is no disclosure of FGF-5 expression in RCC, or how FGF-5 might be used to treat cancers using the CTL-mediated immune response.
  • Gospodarowicz (WO 97/30155) teaches the administration of an FGF-5 nucleic acid sequence, lacking the signal sequence, to promote angiogenesis in patients suffering from myocardial ischemia.
  • the signal sequence was deleted to remove the oncogenic potential of FGF- 5.
  • Gaugler et al. (Immunogenetics . 44:323-30, 1996) and corresponding U.S. Patent No. 5,939,526 describe the identification of RAGEl, a Renal tumor AntiGEn recognized by autologous CTLs. RAGEl was observed in 37% of RCC cell lines, but only in one of 57 renal cell carcinoma samples. RAGEl was also expressed in other cancers including: sarcomas, infiltrating bladder carcinomas, and melanomas, but not expressed in normal tissues, except the retina. Gaugler et al.
  • TAAs recognized by CTLs have been identified in melanomas (for a review see Ki ⁇ kin et al., APMIS. 106:665-79, 1998). These antigens include: MAGE, BAGE, GAGE, PRAME, NY-ESO-1, gp 100, TRP-1, TRP- CDK4, MUM-1, and ⁇ -catenin, some of which have been tested for their ability to treat cancer in vivo. Although some antigens such as MAGE and PRAME should potentially be highly immunogenic, only a few patients have been identified who respond to these TAAs in vivo, indicating their genuinely low immunogenicity. These studies demonstrate that it is difficult to predict with any certainty which TAA will elicit a functional response in vivo. In addition, the need remains to identify alternative TAAs which might generate a greater response in vivo.
  • the disclosure includes a method of treating a subject having a neoplasm expressing or over-expressing FGF-5.
  • the method involves modulating an immune response, such as increasing or decreasing an immune response, or modulating FGF-5 expression or activity, - 4
  • the neoplasm expressing or over-expressing FGF-5 can be a carcinoma, such as an adenocarcinoma.
  • the carcinoma is a carcinoma of the prostate, breast, bladder, or pancreas, or RCC, all of which express or overexposes FGF-5.
  • the neoplasm is a RCC.
  • the method includes modulating an immune response sufficient to stimulate a cytotoxic T cell response to a cell of the FGF-5 expressing or over-expressing neoplasm.
  • the method includes administering a therapeutically effective amount of an agent that modulates an immune response, such as an FGF-5 polypeptide (including variants, polymorphisms, mutants, fusions, and fragments thereof), and immunoreactive sensitized T cells sensitized with FGF-5.
  • Alternative embodiments of the method include administering a therapeutically effective amount of an FGF-5 polypeptide that modulates an immune response to treat a subject having a neoplasm expressing or over-expressing FGF-5.
  • the FGF-5 polypeptide protein has the amino acid sequence shown in either SEQ ID NOS: 4, 6, 8, 10, 12, 16, 18, or 19 or amino acid sequences that differ from those specified in SEQ ID NOS: 4, 6, 8, 10, 12, 16, 18 or 19 by one or more conservative amino acid substitutions, or amino acid sequences having at least 70% sequence identity to those sequences, for example sequences that are at least 80% , 85% , 90% , 95% or even 98% or 99% identical.
  • fragments of the sequences that have or retain such activity may be used.
  • Such fragments may, for example, include at least 50%, 70% , 75% , 90% or 95% of the amino acid residues of the FGF-5 peptide sequence.
  • the sequence is no more than 15 or 20 contiguous residues in length, however longer sequences (such as up to 60 or more amino acids in length) are also included.
  • fragments and variants of the 60 amino acid sequence of SEQ ID NO 19, which includes the HLA-A3 restricted epitope are also included.
  • polypeptide or fragment can be administered to a subject in a therapeutically effective amount sufficient to stimulate an immune response against cells of the tumor
  • alternative embodiments of the disclosure include administering a nucleic acid encoding the FGF-5 polypeptide, or the fragment, polymorphism, or variant thereof, sufficient to stimulate a cytotoxic T cell response.
  • a vector can be administered to the subject which includes a nucleic acid sequence which encodes and expresses FGF-5, or a fragment, polymorphism, or variant thereof, sufficient to stimulate a cytotoxic T cell response to a cell of the neoplasm.
  • the vector is a viral vector, such as a retroviral vector.
  • the FGF-5 polypeptide (including variants, polymorphisms, mutants, fusions, and fragments thereof) that modulates an immune response, can also be administered to the subject by 5 -
  • a host cell expressing a recombinant nucleic acid encoding FGF-5 (including variants, polymorphisms, mutants, fusions, and fragments thereof), sufficient to stimulate a cytotoxic T cell response to a cell of the neoplasm, and inhibit neoplastic proliferation.
  • the inhibition of neoplastic proliferation induces a regression of the tumor, for example as determined by radiographic or other laboratory evidence of disease (such as serologic tumor markers, such as FGF-5 specific binding agents).
  • the T cell response is sufficient to stimulate the T cell to react with a cell of the tumor, such as RCC.
  • the subject can be treated by administering to the subject an effective, neoplasm-inhibiting amount of immunoreactive sensitized T cells, wherein the sensitized T cells are sensitized with FGF-5.
  • the immunoreactive sensitized T cells may be autologous or heterologous.
  • the method includes modulating FGF-5 expression or activity, for example by increasing or decreasing FGF-5 expression or activity.
  • the method includes administering a therapeutically effective amount of an agent that decreases FGF-5 expression or activity, such as an FGF-5 antisense molecule or FGF-5 specific binding agent.
  • the method includes administering a therapeutically effective amount of an agent that increases FGF-5 expression or activity, such as FGF-5 polypeptides and nucleic acids encoding FGF-5 polypeptides.
  • FGF-5 antisense molecules hybridize to an RNA or a plus strand of an FGF-5 nucleic acid (including variants, polymorphisms, mutants, fusions, and fragments thereof) and inhibit FGF-5 expression and/or activity by a desired amount, such as by at least 20% , 50% , 70% , 80% or 90% .
  • the FGF-5 specific binding agent is capable of specifically binding to an FGF-5 polypeptide (including variants, polymorphisms, mutants, fusions, and fragments thereof).
  • the specific binding agent is an antibody, such as polyclonal antibodies, monoclonal antibodies, and fragments of monoclonal antibodies.
  • the disclosure also includes administering the FGF-5 polypeptide, or a fragment or variant, to HLA- A3 + individuals. Individuals can be pre-screened to select HLA- A3 + individuals to whom to administer the FGF-5 polypeptide or fragment.
  • a method for stimulating a cytotoxic T cell response against a RCC, by contacting the T cell with a therapeutically effective amount of an
  • FGF-5 polypeptide or a cell expressing FGF-5 sufficient to stimulate the T cell to react with a cell of the RCC.
  • the disease may be a tumor (such as a malignant tumor) in which FGF-5 is abnormally increased, such as RCC and carcinoma of the prostate, breast, bladder, and pancreas.
  • the disease is Hippel-Lindau disease, horseshoe kidneys, adult polycystic kidney disease, and acquired renal cystic disease.
  • the presence of multiple copies of an FGF-5 and/or transcription factor(s) gene can be detected by incubating a nucleic acid, such as an oligonucleotide, with the nucleic acid of the cell under conditions such that the oligonucleotide will specifically hybridize to an FGF-5 and/or transcription factor(s) gene present in the nucleic acid to form an oligonucleotide: FGF-5 and/or transcription factor(s) gene complex, and then detecting an increase or decrease of oligonucleotide: FGF-5 and/or transcription factor(s) complexes, wherein the presence of said complexes indicates the presence of an FGF-5 and/or transcription factor(s) gene.
  • a nucleic acid such as an oligonucleotide
  • the present disclosure also provides methods for detecting the presence of FGF-5 protein in a cell by incubating a specific binding agent of the present disclosure with proteins of the cell under conditions such that the specific binding agent will specifically bind to an FGF-5 protein present in the cell to form a specific binding agent:FGF-5 protein complex, and detecting an increase or decrease (or quantity) of specific binding agent: FGF-5 protein complexes, including the presence of the FGF-5 protein, wherein an increase of the complexes relative to specific binding agent: FGF-5 protein complexes in a non-neoplastic cell indicates expression or overexpression of FGF-5, and an enhanced susceptibility of the subject to a disease of abnormal FGF-5 expression.
  • the cell is characterized by increased expression of an FGF-5 protein, or the cell has increased FGF-5 expression or copy number, relative to FGF-5 expression in a same tissue type that is non-neoplastic.
  • enhancing the immune response can be achieved by exposing the cell to a therapeutically effective amount of an FGF-5 polypeptide (including fragments, polymorphisms, fusions, and variants) disclosed herein.
  • enhancing the immune response can be achieved by administering a therapeutically effective amount of any FGF-5-expressing nucleic acid (including fragments, polymorphisms, fusions, and variants). In yet other embodiments, enhancing the immune response is achieved by administering a therapeutically effective amount of immuno-reactive sensitized T-cells wherein the sensitized T cells are sensitized with FGF-5.
  • agents disclosed herein can be administered prophylactically, prior to the development of a tumor, for example to persons at elevated risk of developing the tumor (such as persons with a family history of the tumor, and persons with Hippel-Lindau disease, horseshoe 1/25271
  • the agents can also be administered therapeutically, to a person who already has developed the tumor, for example a person who has undergone surgical resection of a RCC primary or metastatic lesion, or a person who is undergoing chemotherapy for treatment of the tumor.
  • the agents can be administered as the sole therapy for the tumor.
  • the agent(s) can be administered with pharmaceutically acceptable carrier.
  • the agents can be administered in combination with other therapeutic treatments, such as other anti-neoplastic or anti-tumorigenic therapies. Such agents can be administered concurrently or sequentially, with the other therapies.
  • FIG. 1 is a bar graph and table showing the analysis of the reactivity of Clone 2 CTL using a panel of tumor lines, and demonstrating HLA-A3 restriction of the CTL response to FGF- 5. The HLA type of each tumor is shown on the right.
  • FIGS. 2A and 2B are bar graphs showing the effect of various anti-HLA monoclonal antibodies on the recognition of tumors by (A) an HLA-A2 restricted CTL or (B) Clone 2 CTL.
  • FIG. 3A is a bar graph illustrating the recognition of three cDNA clones in a HLA-A3 restricted manner by Clone 2 CTL.
  • FIG. 3B is a schematic drawing showing the alignment of the three tumor-derived FGF-5 clones. The nucleotide changes (inside each bar), their positions (under 10E4-1), and any resulting amino acid changes (above each bar) are shown.
  • FIG. 4 is a graphical representation showing the normalization of FGF-5 : ⁇ -actin copy number in normal adult tissues.
  • FIG. 5 is a graphical representation showing the normalization of FGF-5 copy number by ⁇ -actin copy number (filled bars) and the recognition by the CTL as represented by IFN- ⁇ concentration (x), in each cell line. In the insert graph, the correlation between FGF-5 expression and recognition by the CTL (p ⁇ 0.0001) is shown.
  • FIG. 6 is a sequence listing of an FGF-5 ORF-1 and ORF-2 from U.S. Patent No.
  • FIG. 7 is a graphical representation showing FGF-5 peptides that are immunogenic (unfilled bars) and are non-immunogenic (filled bars).
  • the numbers below each bar represent the nucleotide number (upper numbers), and amino acid number (lower numbers) of the FGF-5 sequences shown in SEQ ID NO: 17. 1/25271
  • nucleic and amino acid sequences listed in the accompanying sequence listing are shown using standard letter abbreviations for nucleotide bases, and three letter code for amino acids. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood as included by any reference to the displayed strand.
  • SEQ ID NO 1 shows a DNA sequence for a first open reading frame of MUSFGF-5A.
  • SEQ ID NO 2 shows an amino acid sequence for a first open reading frame of MUSFGF- 5A.
  • SEQ ID NO 3 shows a DNA sequence for a second open reading frame of MUSFGF-5A.
  • SEQ ID NO 4 shows an amino acid sequence for a second open reading frame of MUSFGF-5A.
  • SEQ ID NO 5 shows a cDNA sequence for a variation of IA3-1.
  • SEQ ID NO 6 shows an amino acid sequence for a variation of IA3-1.
  • SEQ ID NO 7 shows a cDNA sequence for another variation of IA3-1.
  • SEQ ID NO 8 shows an amino acid sequence for another variation of IA3-1.
  • SEQ ID NO 9 shows a cDNA sequence for a variation of 6A4-1.
  • SEQ ID NO 10 shows an amino acid sequence for a variation of 6A4-1.
  • SEQ ID NO 11 shows a cDNA sequence for another variation of 6A4-1.
  • SEQ ID NO 12 shows the amino acid sequence for another variation of 6A4-1.
  • SEQ ID NO 13 shows a cDNA sequence for a variation of 10E4-1.
  • SEQ ID NO 14 shows a cDNA sequence for another variation of 10E4-1.
  • SEQ ID NO 15 shows a full-length cDNA sequence of construct 10E4-1 with ORF-1.
  • SEQ ID NO 16 shows an amino acid sequence of ORF-1 from construct 10E4-1.
  • SEQ ID NO 17 shows a full-length cDNA sequence of construct 10E4-1 with ORF-2.
  • SEQ ID NO 18 shows an amino acid sequence of ORF-2 from construct 10E4-1.
  • SEQ ID NO 19 shows a 60 amino acid sequence which contains the FGF-5 epitope for HLA- A3 + individuals.
  • SEQ ID NO 20 and 21 show nucleic acid sequences of forward primers that can be used to RT-PCR FGF-5.
  • SEQ ID NO 22 and 23 show nucleic acid sequences of reverse primers that can be used to RT-PCR FGF-5.
  • SEQ ID NO 24 and 25 show nucleic acid sequences of forward and reverse primers, respectively, that can be used to clone the HLA- A3 gene from autologous 1764 RCC by RT-PCR. • 9 -
  • TILs tumor infiltrating lymphocytes
  • Antineoplastic agent A drug or biologic that inhibits the proliferation of neoplastic cells, for example arresting their growth or causing the regression of a tumor.
  • alkylating agents such as a vincristine, vinblastine or taxol
  • anthracycline antibiotics such as daunorubicin and doxorubicin
  • hormonal therapies such as tamoxifen
  • miscellaneous agents such as cis-diamminedichloroplatimun (II), and hydroxyurea.
  • Antineoplastic agents also include biologies, such as IL-2 and alpha-interferon, and immunotherapy, for example with bacille Calmette-Guerin (BCG). Protocols for administration of such agents are known in the art, and examples can be found in Goodman and Gilman, The Pharmacological Basis of Therapeutics, 17 th edition, section XIII.
  • Antisense molecules or antisense oligonucleotides Nucleic acid molecules that are specifically hybridizable or specifically complementary to either RNA or the plus strand of DNA (Weintraub, Scientific American 262:40, 1990). In the cell, the antisense nucleic acids hybridize to the corresponding mRNA, forming a double-stranded molecule.
  • the antisense oligomer is about 15 nucleotides, which are easily synthesized.
  • the use of antisense molecules to inhibit the in vitro translation of genes is well known in the art (Marcus-Sakura, Anal. Biochem. 172:289, 1988).
  • Therapeutically effective antisense molecules are characterized by their ability to inhibit the expression of FGF-5. Complete inhibition is not necessary for therapeutic effectiveness, some oligonucleotides will be capable of inhibiting the expression of FGF-5 by at least 15% , 30% , 40% , 50%, 60%, 70%, 80% or 90% .
  • Therapeutically effective antisense molecules are additionally characterized by being sufficiently complementary to FGF-5 encoding nucleic acid sequences. As described below, sufficient complementary means that the therapeutically effective oligonucleotide or oligonucleotide analog can specifically disrupt the expression of FGF-5, and not significantly alter the expression of genes other than FGF-5.
  • cDNA complementary DNA: A piece of DNA lacking internal, non-coding segments (nitrons) and regulatory sequences which determine transcription. cDNA is synthesized in the laboratory by reverse transcription from messenger RNA extracted from cells. Chemical synthesis: The artificial means by which one can make a protein or peptide, for example as described in EXAMPLE 17.
  • Deletion The removal of a sequence of DNA, the regions on either side being joined together.
  • DNA Deoxyribonucleic acid.
  • DNA is a long chain polymer which comprises the genetic material of most living organisms (some viruses have genes comprising ribonucleic acid, RNA).
  • the repeating units in DNA polymers are four different nucleotides, each of which comprises one of the four bases, adenine, guanine, cytosine and thymine bound to a deoxyribose sugar to which a phosphate group is attached.
  • Triplets of nucleotides, referred to as codons in DNA molecules code for amino acid in a polypeptide.
  • codon is also used for the corresponding (and complementary) sequences of three nucleotides in the mRNA into which the DNA sequence is transcribed.
  • FGF-5 cDNA is functionally defined as cDNA molecule which encodes a protein having the ability to modulate an immune response, and includes fragments, variants, and polymorphisms of an FGF-5 cDNA that retain the ability to modulate an immune response.
  • the FGF-5 cDNA can be derived by reverse transcription from the mRNA encoded by a FGF-5 gene 1/25271
  • FGF-5 fusion protein A fusion protein comprising a FGF-5 protein (or variants, polymorphisms, mutants, or fragments thereof) linked to other amino acid sequences that do not inhibit the desired activity of FGF-5, for example an immunogenic activity.
  • the other amino acid sequences may be, for example, no more than 10, 20, 30, or 50 amino acid residues in length.
  • FGF-5 Gene A gene which encodes an FGF-5 protein having the ability to modulate an immune response.
  • the definition of a FGF-5 gene includes the various sequence polymorphisms and allelic variations that may exist within a population, or in other species.
  • FGF-5 Protein or FGF-5 Polypeptide A protein encoded by a FGF-5 gene or cDNA, as well as fragments, variants, and polymorphisms that retain the ability to modulate an immune response. This protein may be functionally characterized by its ability to modulate an immune response as described herein.
  • FGF-5 proteins include the full-length FGF-5 transcript (SEQ ID NOS: 4 and 18), as well as shorter peptides (for example SEQ ID NOS: 6, 8, 10, 12, and 19) and fusion proteins which retain the ability to modulate an immune response.
  • FGF-5 RNA The RNA transcribed from a FGF-5 gene.
  • Isolated An "isolated" biological component (such as a nucleic acid, peptide or protein) has been substantially separated, produced apart from, or purified away from other biological components in the cell of the organism in which the component naturally occurs, i.e., other chromosomal and extrachromosomal DNA and RNA, and proteins.
  • Nucleic acids, peptides and proteins which have been “isolated” thus include nucleic acids and proteins purified by standard purification methods.
  • the term also embraces nucleic acids, peptides and proteins prepared by recombinant expression in a host cell as well as chemically synthesized nucleic acids.
  • the method of the present disclosure can include administration of isolated FGF-5 to a subject.
  • Malignant Cells which have the properties of anaplasia invasion and metastasis.
  • Mammal This term includes both human and non-human mammals. Similarly, the term “subject” includes both human and veterinary subjects.
  • Mimetic A molecule (such as an organic chemical compound) that mimics the activity of a protein, such as the ability to modulate an immune response.
  • Peptidomimetic and organomimetic embodiments are within the scope of this term, wherein the three-dimensional arrangement of the chemical constituents of such peptido- and organomimetics mimic the three-dimensional arrangement of the peptide backbone and component amino acid sidechains in the peptide, resulting in such peptido- and organomimetics of the peptides having the ability to stimulate a CTL response against a tumor that is expressing or overexpressing FGF-5.
  • a pharmacophore is an idealized, three-dimensional definition of the structural requirements for - 12 .
  • Peptido- and organomimetics can be designed to fit each pharmacophore with current computer modelmg software (usmg computer assisted drug design or CADD) See Walters, "Computer- Assisted Modeling of Drugs", m Klegerman & Groves, eds , 1993, Pharmaceutical Biotechnology, Interpharm Press Buffalo Grove, IL, pp 165-174 and Principles of Pharmacology (ed Munson, 1995), chapter 102 for a description of techmques used m computer assisted drug design EXAMPLE 16 describes other methods which can be used to generate mimetics
  • Modulating an Immune Response Includes the ability to increase or decrease an immune response m a subject, such as the ability to stimulate a CTL immune response, such as an HLA-A3-rest ⁇ cted CTL response, agamst FGF-5 expressmg or over-expressing tumors, by a desired amount
  • Agents that modulate an immune reponse include, but are not limited to FGF-5 polypeptides (mcludmg fragments, variants, fusion proteins, and polymorphisms thereof), FGF-5 nucleic acid molecules encodmg FGF-5- polpeptides, FGF-5 specific bmdmg agent, FGF-5 antisense molecules, and immunoreactive sensitized T cells sensitized with FGF-5
  • Modulating FGF-5 expression or activity Includes mcreasmg or decreasmg FGF-5 expression or activity
  • modulating FGF-5 expression or activity includes administering a therapeutically effective amount of an agent that decreases FGF-5 expression or activity, such as an FGF-5 antisense molecule or FGF-5 specific bmdmg agent
  • modulating FGF-5 expression or activity mcludes administering a therapeutically effective amount of an agent that mcreases FGF-5 expression or activity, such as the FGF-5 polypeptides and nucleic acids encodmg FGF-5 polypeptides disclosed herem
  • Mutant FGF-5 gene A mutant form of a FGF-5 gene which m some embodiments is associated with disease, for example a carcmoma, such as an adenocarcinoma, RCC, breast cancer, and prostate cancer
  • disease for example a carcmoma, such as an adenocarcinoma, RCC, breast cancer, and prostate cancer
  • the disease is an FGF-5-expressmg tumor, for example RCC, breast, and prostate cancers
  • Mutant FGF-5 protein A protem encoded by a mutant FGF-5 gene
  • Mutant FGF-5 RNA An RNA transcribed from a mutant FGF-5 gene Neoplasm Abnormal growth of cells Normal cells
  • Oligonucleotide A linear polynucleotide sequence of up to about 200 nucleotide bases in length, for example a polynucleotide (such as DNA or RNA) which is at least 6 nucleotides, for example at least 15, 25, 50, 100 or even 200 nucleotides long
  • a first nucleic acid sequence is operably linked with a second nucleic acid sequence when the first nucleic acid sequence is placed m a functional relationship with the /25271
  • a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence.
  • operably linked DNA sequences are contiguous and, where necessary to join two protein-coding regions, in the same reading frame.
  • ORF open reading frame: A series of nucleotide triplets (codons) coding for amino acids without any internal termination codons. These sequences are usually translatable into a peptide.
  • Ortholog Two nucleotide sequences are orthologs of each other if they share a common ancestral sequence, and diverged when a species carrying that ancestral sequence split into two species. Orthologous sequences are also homologous sequences.
  • PCR polymerase chain reaction: Describes a technique in which cycles of denaturation, annealing with primer, and then extension with DNA polymerase are used to amplify the number of copies of a target DNA sequence.
  • compositions useful herein are conventional. Remington's Pharmaceutical Sciences, by E. W. Martin, Mack
  • Embodiments of the disclosure comprising medicaments can be prepared with conventional pharmaceutically acceptable carriers, adjuvants and counterions as would be known to those of skill in the art.
  • parenteral formulations usually comprise injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol, ethanol, sesame oil, combinations thereof, or the like, as a vehicle.
  • the medium may also contain conventional pharmaceutical adjunct materials such as, for example, pharmaceutically acceptable salts to adjust the osmotic pressure, buffers, preservatives and the like.
  • the carrier and composition can be sterile, and the formulation suits the mode of administration.
  • non-toxic solid carriers can include, for example, pharmaceutical grades of mannitol, lactose, starch, sodium saccharine, cellulose, magnesium carbonate, or magnesium stearate.
  • pharmaceutical compositions to be administered can contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate. 14 -
  • the composition can be a liquid solution, suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder.
  • the composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Further embodiments are provided in EXAMPLE 18.
  • Polynucleotide A linear nucleic acid sequence of any length. Therefore, a polynucleotide includes molecules which are 15, 50, 100, 200 (oligonucleotides) and also nucleotides as long as a full length cDNA. In particular embodiments, the polynucleotides are no longer than 15, 50, 100, 120, 180, or 200 nucleotides in length.
  • Probes and primers may readily be prepared based on the amino acid sequences provided herein.
  • a probe comprises an isolated nucleic acid attached to a detectable label or reporter molecule.
  • Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes. Methods for labeling and guidance in the choice of labels appropriate for various purposes are discussed, e.g., in Sambrook et al. , Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1989) and Ausubel et al. , Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley-Intersciences (1987).
  • Primers are short nucleic acids, such as DNA oligonucleotides 15 nucleotides or more in length. Primers may be annealed to a complementary target DNA strand by nucleic acid hybridization to form a hybrid between the primer and the target DNA strand, and then extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification of a nucleic acid sequence, e.g., by PCR or other nucleic-acid amplification methods known in the art.
  • PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, ® 1991, Whitehead Institute for Biomedical Research, Cambridge, MA).
  • Promoter An array of nucleic acid control sequences which direct transcription of a nucleic acid.
  • a promoter includes necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerase II type promoter, a TATA element.
  • a promoter also optionally includes distal enhancer or repressor elements which can be located as much as several thousand base pairs from the start site of transcription.
  • purified does not require absolute purity; rather, it is intended as a relative term.
  • a purified peptide preparation is one in which the peptide or - 15 -
  • a preparation is purified such that the protein or peptide represents at least 50% of the total peptide or protein content of the preparation.
  • the method disclosed herein can include administration of purified FGF-5 to a subject to provoke a CTL response against a tumor that is expressing or overexpressing FGF-5.
  • a recombinant nucleic acid is one that has a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two otherwise separated segments of sequence. This artificial combination can be accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g. , by genetic engineering techniques.
  • Sample Includes biological samples containing genomic DNA, RNA, or protein obtained from body cells, such as those present in peripheral blood, urine, saliva, tissue biopsy, surgical specimen, amniocentesis samples and autopsy material.
  • Sequence identity The similarity between two nucleic acid sequences, or two amino acid sequences, is expressed in terms of the similarity between the sequences, otherwise referred to as sequence identity. Sequence identity is frequently measured in terms of percentage identity (or similarity or homology); the higher the percentage, the more similar the two sequences are. Homologs or orthologs of nucleic acid or amino acid sequences will possess a relatively high degree of sequence identity when aligned using standard methods. This homology will be more significant when the orthologous proteins or cDNAs are derived from species which are more closely related (e.g. , human and chimpanzee sequences), compared to species more distantly related (e.g. , human and C. elegans sequences).
  • FGF-5 orthologs are at least 50% identical at the nucleotide level and at least 50% identical at the amino acid level when comparing orthologus sequences.
  • Methods of alignment of sequences for comparison are well known in the art.
  • Various programs and alignment algorithms are described in: Smith & Waterman, Adv. Appl. Math. 2:482, 1981; Needleman & Wunsch, J. Mol. Biol. 48:443, 1970; Pearson & Lipman, Proc. Natl. Acad. Sci. USA 85:2444, 1988; Higgins & Sha ⁇ , Gene, 73:237-44, 1988; Higgins & Sha ⁇ , CABIOS 5: 151-3, 1989; Co ⁇ et et al., Nuc. Acids Res.
  • NCBI Basic Local Alignment Search Tool (BLAST) (Altschul et at., J. Mol. Biol. 215:403-10, 1990) is available from several sources, including the National Center for Biological Information (NCBI, National Library of Medicine. Building 38A, Room 8N805, Bethesda, MD 16 .
  • Homologs of an FGF-5 protein are typically characterized by possession of at least 70%. 80%, 85%, 90%, 95% , 98% or 99% % sequence identity counted over full-length alignment with the amino acid sequence of FGF-5 using the NCBI Blast 2.0, gapped blastp set to default parameters. Queries searched with the blastn program are filtered with DUST (Hancock, and Armstrong, 1994, Comput. Appl. Biosci. 10:67-70). Other programs use SEG. Alternatively, one may manually align the sequences and count the number of identical amino acids. This number divided by the total number of amino acids in the reference sequence multiplied by 100 results in the percent identity.
  • the Blast 2 sequences function is employed using the default BLOSUM62 matrix set to default parameters, (gap existence cost of 11, and a per residue gap cost of 1).
  • the alignment should be performed using the Blast 2 sequences function, employing the PAM30 matrix set to default parameters (open gap 9, extension gap 1 penalties). Proteins with even greater similarity to the reference sequence will show increasing percentage identities when assessed by this method, such as at least 70%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity.
  • homologs When less than the entire sequence is being compared for sequence identity, homologs will typically possess at least 75% sequence identity over short windows of 10- 20 amino acids, and may possess sequence identities of at least 85%, 90%, 95%, 98% or 99% depending on their similarity to the reference sequence. Methods for determining sequence identity over such short windows are described at the NCBI web site.
  • Stringent conditions are sequence- dependent and are different under different environmental parameters. Generally, stringent conditions are selected to be about 5 C to 20 C lower than the thermal melting point (T m ) for the specific sequence at a defined ionic strength and pH. The T m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence remains hybridized to a perfectly matched probe or complementary strand.
  • T m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence remains hybridized to a perfectly matched probe or complementary strand.
  • nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences, due to the degeneracy of the genetic code. It is understood that changes in nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid molecules that all encode substantially the same protein. Such homologous peptides may, for example, possess at least 70%, 80%, 85%, 90%,
  • homologs may, for example, possess at least 70%, 75%, 85% 90%, 95%, 98% or 99% sequence identity over short windows of 10-20 amino acids. Methods for determining sequence identity over such short windows can be found at the NCBI web site.
  • sequence identity ranges are provided for guidance only; it is entirely possible that strongly significant homologs or other variants could be obtained that fall outside of the ranges provided.
  • the disclosure provides not only the peptide homologs that are described above, but also nucleic acid molecules that encode such homologs.
  • An alternative (and not necessarily cumulative) indication that two nucleic acid sequences are substantially identical is that the polypeptide which the first nucleic acid encodes is immunologically cross reactive with the polypeptide encoded by the second nucleic acid.
  • nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences, due to the degeneracy of the genetic code. It is understood that changes in nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.
  • FGF-5 specific binding agent An agent that binds substantially only to a defined target.
  • FGF-5 specific binding agent includes anti-FGF-5 peptide antibodies and other agents that bind substantially only to an FGF-5 peptide.
  • the antibodies may be monoclonal or polyclonal antibodies that are specific for an FGF-5 peptide, as well as immunologically effective portions (“fragments") thereof.
  • the antibodies used herein are monoclonal antibodies (or immunologically effective portions thereof) and may also be humanized monoclonal antibodies (or immunologically effective portions thereof)- Immunologically effective portions of monoclonal antibodies include Fab, Fab', F(ab') 2 , Fabc and Fv portions (for a review, see Better and Horowitz, Methods. Enzymol. 178:476-96, 1989).
  • Western blottmg may be used to determme that a given FGF-5 peptide binding agent, such as an ant ⁇ -FGF-5 peptide monoclonal antibody, binds substantially only to a FGF-5 protem
  • the specific bmdmg agents disclosed herem may be used to modulate FGF-5 activity, for example to cause regression of an FGF-5 expressing or over- expressing neoplasm
  • specific bmdmg agents of disclosed herem may be used for diagnostic pu ⁇ oses, for example to determme if a subject has an enhanced susceptibility to develop a disease associated with FGF-5 expression or over-expression, or to momtor a subject's progress dur g therapy to treat an FGF-5 expressmg or over-expressing neoplasm
  • oligonucleotide or oligonucleotide analog need not be 100% complementary to its target sequence to be specifically hybridizable
  • An oligonucleotide or analog is specifically hybridizable when bmdmg of the oligonucleotide or analog to the target DNA or RNA molecule mterferes with the normal function of the target DNA or RNA, and there is a sufficient degree of complementarity to avoid non-specific bmding of the oligonucleotide or analog to non-target sequences under conditions m which specific bmdmg is desired, for example under physiological conditions m the case of m vivo assays Such binding is referred to as "specific hybridization " See EXAMPLE 7 for examples of hybridization conditions Subject: Livmg multicellular verte
  • Sufficient complementarity When used, mdicates that a sufficient number of base pairs exist between the oligonucleotide and the target sequence to achieve detectable bmdmg, and disrupt expression of gene products (such as FGF-5) When expressed or measured by percentage of base pairs formed, the percentage complementarity that fulfills this goal can range from as little as about 50% complementarity to full, (100%) complementary In general, sufficient complementarity is at least about 50% In one embodiment, sufficient complementarity is at least about 75% complementarity In another embodiment, sufficient complementarity is about 90% or about 95% complementarity In yet another embodiment, sufficient complementarity is about 98% or 100% complementarity 19
  • Target sequence A portion of single-stranded DNA (ssDNA), double-stranded DNA (dsDNA) or RNA that upon hybridization to an therapeutically effective oligonucleotide or oligonucleotide analog results in the inhibition of VI AF expression.
  • ssDNA single-stranded DNA
  • dsDNA double-stranded DNA
  • RNA RNA that upon hybridization to an therapeutically effective oligonucleotide or oligonucleotide analog results in the inhibition of VI AF expression.
  • an antisense or a sense molecule can be used to target a portion of dsDNA, since both will interfere with the expression of that portion of the dsDNA.
  • the antisense molecule can bind to the plus strand
  • the sense molecule can bind to the minus strand.
  • target sequences can be ssDNA, dsDNA, and RNA.
  • An oligonucleotide "binds” or “stably binds” to a target nucleic acid if a sufficient amount of the oligonucleotide forms base pairs or is hybridized to its target nucleic acid, to permit detection of that binding. Binding can be detected by either physical or functional properties of the target: oligonucleotide complex. Binding between a target and an oligonucleotide can be detected by any procedure known to one skilled in the art, including both functional and physical binding assays. Binding may be detected functionally by determining whether binding has an observable effect upon a biosynthetic process such as expression of a gene, DNA replication, transcription, translation and the like.
  • Physical methods of detecting the binding of complementary strands of DNA or RNA are well known in the art, and include such methods as DNase I or chemical footprinting, gel shift and affinity cleavage assays, Northern blotting, dot blotting and light abso ⁇ tion detection procedures.
  • one method that is widely used involves observing a change in light abso ⁇ tion of a solution containing an oligonucleotide (or an analog) and a target nucleic acid at 220 to 300 nm as the temperature is slowly increased. If the oligonucleotide or analog has bound to its target, there is a sudden increase in abso ⁇ tion at a characteristic temperature as the oligonucleotide (or analog) and target disassociate or melt.
  • T m The binding between an oligomer and its target nucleic acid is frequently characterized by the temperature (T m ) at which 50% of the oligomer is melted from its target.
  • T m the temperature at which 50% of the oligomer is melted from its target.
  • a higher (T m ) means a stronger or more stable complex relative to a complex with a lower (T m ).
  • Therapeutically Effective Amount The preparations disclosed herein are administered in therapeutically effective amounts.
  • An effective amount is that amount of a pharmaceutical preparation that alone, or together with further doses, stimulates the desired response.
  • the desired response is inhibiting or stopping the progression of the cancer, or inducing regression of the disease. Treatment may involve only slowing the progression of the - 20 '
  • disease temporarily, although more preferably, it involves halting or reversing the progression of the disease permanently.
  • the therapeutically effective amount also includes a quantity of FGF-5 protein, fusion protein, FGF-5 antisense molecule, FGF-5 specific binding agent, and/or autologous CTLs specific to FGF-5, sufficient to achieve a desired effect in a subject being treated. For instance, this can be the amount necessary to improve signs and/or symptoms a disease such as cancer, for example by modulating, for example increasing a CTL response against a tumor expressing or overexpressing FGF-5.
  • an effective amount of FGF-5 protein, FGF-5 antisense molecule, FGF-5 specific binding agent, and/or autologous CTLs specific to FGF-5 may be administered in a single dose, or in several doses, for example daily, during a course of treatment.
  • the effective amount of will be dependent on the source applied (i.e. FGF-5 isolated from a cellular extract versus a chemically synthesized and purified FGF-5, or a variant or fragment that may not retain full FGF-5 activity), the subject being treated, the severity and type of the condition being treated, and the manner of administration.
  • a therapeutically effective amount of FGF-5 protein, FGF- 5 antisense molecule, FGF-5 specific binding agent, and/or autologous CTLs specific to FGF-5 can vary from about 0.01 mg/kg body weight to about 1 g/kg body weight.
  • the general term "subject being treated” is understood to include all animals (e.g. humans, apes, dogs, cats, horses, and cows) that require modulation of a CTL response against a tumor that is expressing or overexpressing FGF-5.
  • Therapeutically effective dose A dose sufficient to stimulate a CTL response to a tumor expressing or over-expressing FGF-5, resulting in a regression of a pathological condition, or which is capable of relieving signs or symptoms caused by the condition, such as regression of the tumor and/or lysis of the cells of the tumor.
  • a transformed cell is a cell into which has been introduced a nucleic acid molecule by molecular biology techniques.
  • transformation encompasses all techniques by which a nucleic acid molecule might be introduced into such a cell, including transfection with viral vectors, transformation with plasmid vectors, and introduction of naked DNA by electroporation, lipofection, and particle gun acceleration.
  • Transgenic Cell Transformed cells which contain foreign, non-native DNA.
  • Tumor A neoplasm
  • FGF-5 protein The production of FGF-5 protein can be accomplished in a variety of ways (for example see EXAMPLE 8).
  • DNA sequences which encode for the protein, or a fragment or variant of the protein, can be engineered such that they allow the protein to be 21
  • the DNA sequence can be altered and operably linked to other regulatory sequences.
  • the final product which contains the regulatory sequences and the therapeutic protein, is referred to as a vector.
  • This vector can then be introduced into the eukaryotic cells, bacteria, insect, and/or plant. Once inside the cell the vector allows the protein to be produced.
  • DNA can be altered in numerous ways without affecting the activity of the encoded protein.
  • PCR may be used to produce variations in the DNA sequence which encodes FGF-5.
  • variants may be variants that are optimized for codon preference in a host cell that is to be used to express the protein, or other sequence changes that facilitate expression.
  • cDNA sequence variant Two types may be produced.
  • the variation in the cDNA sequence is not manifested as a change in the amino acid sequence of the encoded polypeptide. These silent variations are simply a reflection of the degeneracy of the genetic code.
  • the cDNA sequence variation does result in a change in the amino acid sequence of the encoded protein.
  • the variant cDNA sequence produces a variant polypeptide sequence.
  • any such amino acid substitutions may be conservative. Conservative substitutions replace one amino acid with another amino acid that is similar in size, hydrophobicity, etc.
  • Variations in the cDNA sequence that result in amino acid changes, whether conservative or not, are minimized to enhance preservation of the functional and immunologic identity of the encoded protein.
  • the immunologic identity of the protein may be assessed by determining whether it is recognized by an antibody to FGF-5; a variant that is recognized by such an antibody is immunologically conserved.
  • any cDNA sequence variant will introduce no more than 20, for example fewer than 10 amino acid substitutions into the encoded polypeptide.
  • Variant amino acid sequences can, for example, be 70%, 80%, 90% or even 95% identical to the native amino acid sequence.
  • conserved residues in the same or similar proteins from different species can also provide guidance about possible locations for making substitutions in the sequence.
  • a residue which is highly conserved across several species is more likely to be important to the function of the protein than a residue that is less conserved across several species.
  • a nucleic acid molecule as introduced into a host cell, thereby producing a transformed host cell.
  • a vector may include nucleic acid sequences that permit it to replicate in a host cell, such as an origin of replication.
  • a vector may also include one or more selectable marker genes and other genetic elements known in the art. - 22
  • TIL tumor infiltrating lymphocytes
  • Clone 2 recognized a product of the fibroblast growth factor-5 (FGF-5) gene.
  • FGF-5 fibroblast growth factor-5
  • Direct sequencing of genomic DNA from autologous EBVB cells showed no mutations in the putative amino acid sequence for FGF-5 in tumor-derived cDNA, indicating that a tumor-specific mutation is not the basis of immune recognition by Clone 2.
  • FGF-5 was not expressed in normal adult organs, and was over-expressed in multiple renal cell carcinomas, prostate carcinomas, and a breast carcinoma. Expression of FGF-5 by renal and other tumors corresponded to the recognition of these tumor cells in an HLA- A3 restricted fashion.
  • TILs Tumor Infiltrating Lymphocytes
  • This example describes the isolation of TILs from a metastatic RCC lung lesion. Similar methods can be used to isolate TILs from other neoplasms.
  • the surgically resected remnant of a spontaneously regressing metastatic RCC lung lesion was enzymatically digested (0.1 % Collagenase type IV, 30u/ml deoxyribonuclease type IV, and 0.01% hyaluronidase type V [Sigma, St. Louis, MO]) at room temperature (RT) for three hours. After digestion, the cell suspension was filtered through 100 ⁇ m nylon mesh and separated by density gradient using Lymphocyte Separation Medium (Organon Teknica, Durham, NC).
  • lymphocyte-containing interface was recovered, washed with Hanks' Balanced Salt Solution, and used for TIL culture in RPMI (Biofluids, Rockville, MD) 10% human AB serum (Biochemed Pharmacologicals, Winchester, VA) with 6000 IU/ml of recombinant human IL-2 (Chiron Co ⁇ ., 23
  • Emoryville, CA in 24 well plates at a cell density of 1 x 10 6 cells/well.
  • the culture was stimulated every two weeks with an irradiated autologous RCC cell line established from a primary left nephrectomy sample (EXAMPLE 2).
  • EBV-B cell line was established by EBV infection using a culture supernatant of cell line B95-9 (American Type Culture Collection, ATCC, Manassas, VA).
  • An autologous fibroblast line was established by infecting a one-week old cultured tumor sample with a retrovirus that encoded the papilloma virus E6/E7 proteins and performing limiting dilution.
  • RCC cell lines UOK125, UOK127, UOK130, UOK131, UOK150, and UOK 171 were obtained from Dr. W. Marston Linehan (NCI, Bethesda, MD).
  • Lung cancer cell lines SKGT2, SKGT4, SKGT5 and esophageal cancer cell line HCE-4 were obtained from Dr.
  • EXAMPLE 2 Identification of a CTL Clone with Specific Recognition of Autologous RCC
  • a TIL line When cultured in media with IL-2.
  • This bulk TIL line was stimulated periodically with an irradiated autologous tumor cell line established from a left nephrectomy operation sample. After three months of culture, the autologous tumor-specific T cell clone (Clone 2 CTL) was established by limiting dilution of the bulk TIL line.
  • Clone 2 CTL was CD30 CD8 ⁇ and was found to utilize V ⁇ l2 by PCR-based TCR (T-cell receptor) analysis.
  • the reactivity of Clone 2 CTL was assessed using an autologous RCC cell line (1764 CTL), an autologous EBV-B cell line, an autologous fibroblast cell line, and other allogeneic RCC cell lines described in EXAMPLE 1.
  • RCC cells (5 x 10 4 cells/well), fibroblasts (5 x 10 4 cells), or EBV-B cells (1 x 10 6 cells/well) were plated into 96 well flat bottom plates and 2 x 10 4 cells/well of Clone 2 CTL were added. After incubating for 20 hours, supernatants were harvested and IFN- ⁇ concentration was analyzed by ELISA (Endogen, Woburn, MA), where IFN- ⁇ concentration is considered proportional to CTL activation.
  • ELISA plates (96 well flat bottom, Costar, NY) were coated with anti-human IFN- ⁇ monoclonal antibody (2G1, ENDOGEN, MA) at 1 ⁇ g/ml, 100 ⁇ l/well overnight. After washing, plates were blocked with PBS-5% FBS (fetal bovin serum) for one hour (200 ⁇ l/well), the samples added (100 ⁇ l/well) and incubated for 90 minutes. Subsequently, the plates were washed and biotin-labeled anti-human IFN- ⁇ monoclonal antibody (B133.5, ENDOGEN, MA) was added at 0.5 - 24 -
  • Irradiated tumor cells (5 x 10 4 cells in 100 ⁇ l) were incubated with mAbs (20 ⁇ g/ml) for 30 minutes at RT, and 2 x 10" CTL were added. Following 20 hours of culture at 37 °C, the supernatant was assayed for IFN- ⁇ concentration by ELISA as described above.
  • a control FIG. 2A
  • a CTL and autologous tumor target whose interaction is known to be restricted by HLA-A2 was used.
  • the effect of a blocking mAb on the recognition of autologous tumor by Clone 2 CTL is shown in FIG.
  • RNA was prepared from the autologous RCC cell line using a mRNA isolation system (Fast Track kit 2.0; Invitrogen, Carlsbad, CA).
  • cDNA was prepared with the Superscript plasmid system (Life Technologies, Rockville, MD) and ligated into the eukaryotic plasmid expression vector pME18S (Dr. Atsushi Miyajima, University of Tokyo). After electroporation and titration, a cDNA library was prepared in pools by inoculating approximately 100 bacterial clones/well in 1 ml LB/well and purifying - 25
  • COS-7 cells were retrovirally transduced with the HLA- A3 gene derived from the autologous tumor cell line.
  • the HLA-A0201 gene was retrovirally transduced into COS-7 cells (hereafter referred to as COS-A3 or COS-A2, respectively).
  • HLA-A3 To introduce HLA-A3 into non-HLA-A3-expressing cells, the HLA- A3 gene was cloned from autologous 1764 RCC by RT-PCR (forward primer 5'- TTGGGGAGGGAGCACAGGTCAGCGTGGGAAG-3' , SEQ ID NO: 24; reverse primer 5'- GGACTCAGAATCTCCCCAGACGCCGAG-3' , SEQ ID NO: 25), sequenced, and subcloned into the retroviral vector pRx-IRES-Bsr (Wakimoto et al , Jpn. J. Cancer Res. 88:296-305, 1997).
  • Vesicular stomatitis virus G protein-pseudotyped retrovirus was prepared by transiently transfecting the 293 GP cell line using standard methods (see Wang et al. , Cancer Res. 58:3519-25, 1998, inco ⁇ orated by reference). Forty-eight hours after transfection, culture supernatant was harvested, filtered, and used for infection with 8 ⁇ g/ml of polybrene. Infection efficiencies ranged from 70%- 100% and the HLA-A3 positive population was further selected by 5 ⁇ g/ml of blasticidin S (Calbiochem, San Diego, CA).
  • IA3 (SEQ ID NOS: 7 and 8), 6A4 (SEQ ID NOS: 11 and 12), and 10E4 (SEQ ID NOS: 13-18) selected after subcloning reactive cDNA pools were transfected (100 ng of plasmid) into 5 x 10 4 COS-A2 and COS-A3 using 1 ⁇ l of lipofectAMINE (Life Technologies, Rockville, MD) in 96-well plates according to the manufacturer's instructions. The next day, Clone 2 CTL (2 x 10 4 cells/well) were added and after 20 hours incubation, supernatants were assayed for IFN- ⁇ secretion by Clone 2 CTL as described in the above EXAMPLES. An FGF-5 gene from an independent source (FGF-5 MG, from Dr. Mitchell Goldfarb, Mount Sinai School of Medicine) was analyzed the same way.
  • the measured IFN- ⁇ concentration is greater than 2500 pg/ml for the COS- A3 cells, but less than 1 pg/ml for the COS-A2 cells.
  • the clones that conferred recognition of COS-A3 by the CTL were identified and sequenced on an automated sequencer (ABI Prizm 310; Perkin-Elmer Co ⁇ ., Foster City, CA).
  • the sequence of the clones is similar, but not identical to, the human FGF-5 sequence from GenBank Accession No M37825 (MUSFGF5A; SEQ ID NOS 1-4 and FIG. 6).
  • MUSFGF5A GenBank Accession No M37825
  • the smallest cDNA clone (FIG.
  • FGF-5 MG FGF-5 cDNA from an independent source
  • Clone 2 CTL Clone 2 CTL
  • SEQ ID NO: 7 The DNA sequence of the FGF-5 MG plasmid was identical to clone 1A3-1 (SEQ ID NO: 7). Therefore, the previously published FGF-5 sequence available on GenBank Accession No. M37825 contains at least eight nucleotide and four amino acid differences.
  • FGF-5 peptide may be immunogenic for individuals who are not HLA- A + (for example HLA-A2 + subjects, who constitute about 50% of the Caucasian population).
  • amino acid sequences as short as eight contiguous amino acid residues for example 8-12, or 20 or less residues of FGF-5 (SEQ ID NOS: 4, 6, 8, 10, 12, and 16-19) are included within the present disclosure.
  • sequences at least 60 contiguous residues for example at least 80, 100, 120, 140, 160, 180, 200, 220 or 240 contiguous amino acids of the sequence shown in FIG. 6, or SEQ ID NOS: 3 or 18 are suitable for use with this method.
  • RT-PCR real-time-PCR
  • INF- ⁇ release was measured in normal cells, tumor cells naturally expressing HLA- A3, and in non-HLA-A3 expressing tumors in which HLA- A3 was introduced by retroviral transduction (see EXAMPLE 3). Similar methods can be used to analyze FGF-5 expression in any sample from any organism.
  • RNA of normal adult human tissues were purchased from Clontech Laboratories (Palo Alto, CA).
  • Total RNA from tumor cell lines were prepared using the RNeasy mini kit according to the manufacturer's instructions (Qiagen, Valencia, CA).
  • First strand cDNA was synthesized using the Superscript Preamplification System (Life Technologies, Rockville, MD) utilizing 5 ⁇ g of total - 27 -
  • RNA from either normal tissue or tumor cell lines For the analysis, 2 ⁇ l out of 20 ⁇ l of the first strand cDNA was used. Two forward primers (FGF-F1 5'-CTTCTTCAGCCACCTGATCCTC (SEQ ID NO: 20) and FGF-F2 5'-TGCAGAGTGGGCATCGGTTTC (SEQ ID NO: 21)) were planned in exon 1 and two reverse primers (FGF-Rl 5'-TATGCTCAATGCAGAGGTAC (SEQ ID NO: 22) and FGF-R2 5'-CGTAGTCCCTGTTATTTAAC (SEQ ID NO: 23)) were planned in exon 3.
  • FGF-F1 5'-CTTCTTCAGCCACCTGATCCTC SEQ ID NO: 20
  • FGF-F2 5'-TGCAGAGTGGGCATCGGTTTC SEQ ID NO: 21
  • FGF-Rl 5'-TATGCTCAATGCAGAGGTAC SEQ ID NO: 22
  • the first PCR reaction was performed at 94 °C for one minute followed by 16 cycles of 94 °C for 30 seconds, 61 °C for 45 seconds, and 72 °C for 60 seconds.
  • 2 ⁇ l out of 50 ⁇ l of the first PCR reaction was used with the primer pair of F2 and R2 using the same PCR program.
  • the PCR product (10 ⁇ l) was subjected to agarose gel analysis. As a control, the expression level of ⁇ -actin was also measured.
  • tumor cells (5 x 10 4 ) were plated in flat bottom 96 well plates and 2 x 10 4 Clone 2 CTL were added. After incubating for 20 hours, the supernatants were assayed for IFN- ⁇ concentration by ELISA as described above in EXAMPLE 2.
  • FGF-5 copy number was normalized to ⁇ -actin copy number in each cell line and the FGF-5 copy number/ 10 s ⁇ -actin copy number plotted (filled bars in FIGS. 4 and 5).
  • FGF-5 expression was below the level of detection.
  • FGF-5 was only detectable in brain and kidney.
  • the FGF-5 copy number in these tissues was lower than the calculated recognition threshold for CTL clone 2 (FIG. 5). No detectable FGF-5 expression was observed in normal tissues using Northern blotting.
  • FGF-5/10 5 ⁇ -actin copies for example at least 500 FGF-5/10 5 ⁇ -actin copies, for example at least 1000 FGF-5/10 5 ⁇ -actin copies, are expected to generate an immune response.
  • This example describes how the expression of FGF-5 by tumor cells can be used to stimulate the immune system for cancer therapies.
  • the immune therapy is preceded by determining whether FGF-5 expression is increased, for example using the method of EXAMPLE 4.
  • the immune therapy can then be administered if FGF-5 expression is found to be increased in the tumor cell.
  • the methods disclosed herein can also be combined with other antineoplastic treatments, such as radiotherapy or administration of anti-neoplastic drugs or biologies.
  • FGF-5 satisfies several criteria as a tumor antigen for cancer therapy. It is expressed substantially specifically in tumors but not in normal tissues in humans, particularly adults (FIGS. 4 and 5 A and 5B). Although FGF-5 expression has been reported at a low level in brain (Goldfarb et al. Ann. NY Acad. Sci. 638:38-52, 1991), FGF-5 was not detected by RT-PCR in brain tissue, even though RT-PCR was sensitive enough to detect FGF-5 expression in tumors. Hence FGF-5 expression in adult human brain is low, if present at all. As an immunologically privileged site, the central nervous system is also unlikely to be an auto-immune target during FGF-5 targeted immunotherapy.
  • FGF-5 is a non-mutated antigen, over-expressed in some RCC, breast carcinomas, and prostate cancers (FIGS. 5 A and 5B). According to the literature, FGF-5 is over-expressed in bladder cancers and pancreatic cancers (Yoshimura et al , Cancer Lett. 103:91-7, 1996; Kornman et al. Oncogene 15: 1417-24, 1997). Therefore it represents an attractive tumor antigen for these cancers, and particularly such cancers which lack identified vaccine targets.
  • tumor-specific antigens are categorized in three groups; 1) tissue differentiation antigens (e.g. MART-1 , tyrosinase, gplOO); 2) tumor-specific mutations (e.g. ⁇ -catenin, CASP-8); and 3) proteins sharing expression on tumor and testis (e.g. MAGE-1 , BAGE).
  • tissue differentiation antigens e.g. MART-1 , tyrosinase, gplOO
  • tumor-specific mutations e.g. ⁇ -catenin, CASP-8
  • proteins sharing expression on tumor and testis e.g. MAGE-1 , BAGE.
  • Recently antigens overexpressed on tumors but not expressed by testis have been described (e.g. telomerase catalytic subunit (hTERT), ⁇ 53).
  • FGF-5 is believed to belong to this new class of tumor antigens.
  • FGF-5 A therapeutic directed against FGF-5 is believed to have substantial therapeutic potential to interfere with important biological functions of tumors, since FGF-5 is believed to have an • 29 -
  • FGF-5 was originally identified as an oncogene that transformed NIH-3T3 cells (Zhan et al, Mol. Cell. Biol. 8:3487-95, 1988). In pancreatic cancer, FGF-5 is believed to have autocrine and paracrine growth-promoting activities, and to function as an angiogenic factor such that it may therefore be suitable as an anti-angiogenic target.
  • PBMCs peripheral blood mononuclear cells
  • PBMCs peripheral blood mononuclear cells
  • a sample of cells taken from a subject are contacted with a cell presenting the complex and capable of provoking CTLs to proliferate.
  • the target cell can be a transfectant, such as a COS cell of the type described above. These transfectants present the desired HLA complex on their surface and, when combined with a CTL of interest, stimulate proliferation of the CTL of interest.
  • COS cells such as those used herein, are widely available, as are other suitable host cells. Specific production of a CTL clone has been described above. The clonally expanded autologous CTLs may then be administered to the subject.
  • CTLs can also be stimulated in vivo, using a number of approaches.
  • One approach is the use of non-proliferative cells expressing the complex of FGF-5 and an HLA presenting molecule (such as HLA- A3), to stimulate an immune response.
  • the cells used in this approach may be those 30 -
  • vectors carrying one or both of the genes of interest may be used, such as viral or bacterial vectors (EXAMPLE 14).
  • nucleic acids which encode FGF-5 may be operably linked to promoter and enhancer sequences which direct expression of the FGF-5 in certain tissues or cell types. The nucleic acid may be inco ⁇ orated into an expression vector (EXAMPLE 8).
  • Expression vectors may be unmodified extrachromosomal nucleic acids, plasmids or viral genomes constructed or modified to enable insertion of exogenous nucleic acids, such as those encoding FGF-5.
  • Nucleic acids encoding FGF-5 also may be inserted into a retroviral genome, thereby facilitating integration of the nucleic acid into the genome of the target tissue or cell type.
  • the gene of interest is carried by a microorganism, e.g., a Vaccinia virus or retrovirus, which infect host cells. The cells which result present the complex of interest and are recognized by autologous CTLs, which then proliferate.
  • a similar effect can be achieved by combining the FGF-5, or a stimulatory fragment thereof, with an adjuvant to facilitate inco ⁇ oration into cells (such as HLA-A3 presenting cells) in vivo.
  • an adjuvant to facilitate inco ⁇ oration into cells (such as HLA-A3 presenting cells) in vivo.
  • subjects receive an intradermal injection of an effective amount of the FGF-5, and/or immunogenic fragments or variants derived therefrom. Initial doses can be followed by booster doses, following immunization protocols standard in the art.
  • substances which potentiate the immune response may be administered with nucleic acid or peptide components of a cancer vaccine.
  • immune response potentiating compounds may be classified as either adjuvants or cytokines.
  • Adjuvants may enhance the immunological response by providing a reservoir of antigen (extracellularly or within macrophages), activating macrophages and stimulating specific sets of lymphocytes.
  • Adjuvants of many kinds are well known in the art; specific examples include MPL (SmithKline Beecham), a congener obtained after purification and acid hydrolysis of Salmonella minnesota Re 595 lipopolysaccharide, QS21 (SmithKline Beecham), a pure QA-21 saponin purified from Quillja saponaria extract, and various water-in-oil emulsions prepared from biodegradable oils such as squalene and/or tocopherol. Cytokines are also useful in vaccination protocols as a result of lymphocyte stimulatory properties. Many cytokines useful for such pu ⁇ oses will be known to one of ordinary skill in the art, including interleukin-12 (IL-12) which has been shown to enhance the protective effects of vaccines (Science 268: 1432-4, 1995). - 31 -
  • IL-12 interleukin-12
  • the therapeutic compositions of the present disclosure may be, for example, administered in pharmaceutically acceptable preparations (EXAMPLE 18).
  • Such preparations may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives, compatible carriers, supplementary immune potentiating agents such as adjuvants and cytokines and optionally other therapeutic agents (including other anti-neoplastic agents).
  • cytotoxic lymphocyte immune response When it is desired to stimulate a cytotoxic lymphocyte immune response using a therapeutic composition disclosed herein, it is believed that doses of immunogens ranging from one nanogram/kilogram to 100 miligrams/kilogram, depending upon the mode of administration, would be effective.
  • the range may, for example, be between 500 nanograms and 500 micrograms per kilogram.
  • the absolute amount will depend upon a variety of factors, including the material selected for administration, whether the administration is in single or multiple doses, and individual subject parameters including age, physical condition, size, weight, and the stage of the disease. These factors are well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation.
  • Nucleic acid probes and primers can be readily prepared based on the nucleic acid molecules provided herein (SEQ ID NOS: 3, 5, 7, 9, 11, 13-15, 17 and FIG. 6).
  • a probe comprises an isolated nucleic acid attached to a detectable label or reporter molecule.
  • Typical labels include radioactive isotopes, enzyme substrates, co-factors, ligands, chemiluminescent or fluorescent agents, haptens, and enzymes. Methods for labeling and guidance in the choice of labels appropriate for various pu ⁇ oses are discussed, e.g., in Sambrook et al. (In Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, New York, 1989) and Ausubel et al. (In Current Protocols in Molecular Biology, Greene Publ. Assoc. and Wiley-Intersciences, 1992).
  • Primers are short nucleic acid molecules, such as DNA oligonucleotides 15 nucleotides or more in length. Primers can be annealed to a complementary target DNA strand by nucleic acid hybridization to form a hybrid between the primer and the target DNA strand, and then the primer extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification of a nucleic acid sequence, e.g. , by the polymerase chain reaction (PCR) or other nucleic-acid amplification methods known in the art.
  • PCR polymerase chain reaction
  • PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that pu ⁇ ose such as Primer (Version 0.5, ® 1991 , Whitehead Institute for Biomedical Research, Cambridge, MA).
  • Primer Version 0.5, ® 1991 , Whitehead Institute for Biomedical Research, Cambridge, MA.
  • a primer comprising 20 consecutive nucleotides of the FGF-5 gene will anneal to a target sequence.
  • probes and primers can be selected that comprise 20, 25, 30, 35, 40, 50 or more consecutive nucleotides of FGF-5 gene sequences.
  • the disclosure thus includes isolated nucleic acid molecules that comprise specified lengths of the disclosed gene sequences. Such molecules may comprise at least 20, 25, 30, 35, 40 or 50 consecutive nucleotides of these sequences, and may be obtained from any region of the disclosed sequences.
  • the gene sequences may be apportioned into halves or quarters based on sequence length, and the isolated nucleic acid molecules may be derived from the first or second halves of the molecules, or any of the four quarters.
  • the probes and primers can be used for the detection of FGF-5 DNA and the detection of specific mutations or polymo ⁇ hisms associated with tumor development or prognosis.
  • FGF-5 The amino acid sequences of FGF-5 (SEQ ID NOS: 4, 6, 8, 10, 12, and 16-19 and FIG. 6) encoded by FGF-5 cDNAs (SEQ ID NOS: 3, 5, 7, 9, 11, 13-15, 17 and FIGS. 3C and 6) are disclosed.
  • the distinctive functional characteristic of FGF-5 is its ability to modulate an immune response, for example the ability to stimulate an HLA-A3-restricted CTL immune response against FGF-5 expressing or over-expressing tumors, as measured by IFN- ⁇ concentration. This activity is reduced by about at least 50% , for example 75%, in the presence of pan-anti-class I MHC mAb (such as W6/32) or anti-HLA-A3 mAb (such as GAP A3).
  • FGF-5 Another distinctive functional characteristic of FGF-5 is the observation that FGF-5 is expressed at undetectable levels in normal adult tissues, but is expressed or over-expressed in some cancers, such as RCC, prostate and breast carcinomas. These activities of FGF-5 proteins may readily be determined using the assays described above, for example those described in EXAMPLES 2-4.
  • FGF-5 variants, polymo ⁇ hisms, mutants, and fragments will retain the ability to modulate an immune response, for example stimulate an immune response, for example, an HLA-A3- restricted CTL immune response.
  • an immune response in particular embodiments, induces a regression of the FGF-5 expressing tumor.
  • pan-anti-class I MHC mAb such as W6/32
  • anti-HLA-A3 mAb such as GAPA3
  • the stimulated immune response such as an HLA-A3- restricted CTL immune response, is blocked. This as observed by an at least 50% decrease in IFN- ⁇ concentration using the assay described in EXAMPLE 2.
  • Substitutions of FGF-5 amino acid sequences can be made either in regions that are highly conserved between species, or regions that share less conservation between species.
  • regions of FGF-5 which are highly conserved between species ideally do not substantially diverge from the wild-type sequence shown in SEQ ID NOS: 4, 6, 8, 10, 12, and 16- 19 and FIG. 6.
  • Other important residues include the receptor binding domain and the heparin binding domain (both located in the center of the protein).
  • Other important residues include amino acids 161-220 of FGF-5 (shown in SEQ ID NO: 19). In these regions, conservative substitutions will be better tolerated than non-conservative substitutions. Alterations in regions that are less conserved are predicted to have less of an effect on the function of the FGF-5 protein.
  • Variants and fragments may retain at least 60 % , 70 % , 75 % 80 % , 85 % , 90 % , 95 % , 98 % , or greater sequence identity to the FGF-5 amino acid sequences disclosed herein, and in particular embodiments at least this much identity to SEQ ID NOS: 4, 6, 8, 10, 12, and 16-19 and FIG. 6. Less identity is allowed, as long as the variant FGF-5 sequence maintains the functional activity of the FGF-5 protein as defined herein. Such activity can be readily determined using the assays disclosed herein.
  • substitutional variants are those in which at least one residue in the amino acid sequence has been removed and a different residue inserted in its place. Such substitutions 34 -
  • amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative substitutions include: Ser for Ala; Lys for Arg; Gin or His for Asn; Glu for Asp; Ser for Cys; Asn for Gin; Asp for Glu; Pro for Gly; Asn or Gin for His; Leu or Val for He; He or Val for Leu; Arg or Gin for Lys; Leu or He for Met; Met, Leu or Tyr for Phe; Thr for Ser; Ser for Thr; Tyr for T ⁇ ; T ⁇ or Phe for Tyr; and He or Leu for Val.
  • Amino acid substitutions are typically of single residues, for example 1, 2, 3, 4, 5, 10 or more substitutions; insertions usually will be on the order of about from 1 to 10 amino acid residues; and deletions will range about from 1 to 30 residues. Substitutions, deletions, insertions or any combination thereof may be combined to arrive at a final construct. Obviously, the mutations that are made in the DNA encoding the protein must not place the sequence out of reading frame and preferably will not create complementary regions that could produce secondary mRNA structure.
  • Changes in function or immunological identity are made by selecting substitutions that are less conservative than those listed above, i.e., selecting residues that differ more significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.
  • substitutions which in general are expected to produce the greatest changes in protein properties will be those in which (a) a hydrophilic residue, e.g., seryl or threonyl, is substituted for (or by) a hydrophobic residue, e.g., leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue having an electropositive side chain, e.g., lysyl, arginyl, or histadyl, is substituted for (or by) an electronegative residue, e.g., glutamyl or aspartyl; or (d) a residue having a bulky side chain, e.g., phenylalanine, is substituted for (or by) one not having a side chain, e.g., glycine.
  • a hydrophilic residue e.g
  • FGF-5 variants can be readily selected for additional testing by performing an assay (such as that shown in EXAMPLES 2-4) to determine if the FGF-5 variant retains the ability ro stimulate an HLA-A3-restricted CTL immune responsejagainst FGF-5 expressing or over-expressing tumors, as measured by IFN- ⁇ concentration.
  • Variant DNA molecules include those created by standard DNA mutagenesis techniques, for example, M13 primer mutagenesis. Details of these techniques are provided in Sambrook et al. (In: Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, New York, 1989, Chapter 15, herein inco ⁇ orated by reference). By the use of such techniques, variants may be created which differ in minor ways from those disclosed. DNA molecules and nucleotide sequences which are derivatives of those specifically disclosed herein and which differ from those disclosed by the - 35 -
  • small DNA molecules which are derived from the disclosed DNA molecules.
  • Such small DNA molecules include oligonucleotides suitable for use as hybridization probes or PCR primers.
  • these small DNA molecules will comprise at least a segment of FGF-5 cDNA molecules or FGF-5 genes.
  • the sequences will comprise at least 20, 25, 30, 40, or 50 contiguous nucleotides of nucleotide sequence of FGF-5 (SEQ ID NOS: 3, 5, 7, 9, 11 , 13-15, 17 and FIG. 6, or their complementary strands) (i.e. , at least 20-50 consecutive nucleotides of the FGF-5 cDN A/gene sequences).
  • SEQ ID NOS: 3, 5, 7, 9, 11 , 13-15, 17 and FIG. 6, or their complementary strands i.e. , at least 20-50 consecutive nucleotides of the FGF-5 cDN A/gene sequences.
  • DNA molecules and nucleotide sequences which are derived from the disclosed DNA molecules as described above may also be defined as DNA sequences which hybridize under stringent conditions to the DNA sequences disclosed, or fragments thereof.
  • Hybridization conditions resulting in particular degrees of stringency will vary depending upon the nature of the hybridization method of choice and the composition and length of the hybridizing DNA used. Generally, the temperature of hybridization and the ionic strength (especially the Na + concentration) of the hybridization buffer will determine the stringency of hybridization. Calculations regarding hybridization conditions required for attaining particular degrees of stringency are discussed by Sambrook et al. (In: Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, New York, 1989 ch. 9 and 11), herein inco ⁇ orated by reference.
  • Specific hybridization refers to the binding, duplexing, or hybridizing of a molecule only or substantially only to a particular nucleotide sequence when that sequence is present in a complex mixmre (e.g. total cellular DNA or RNA). Specific hybridization may also occur under conditions of varying stringency.
  • a complex mixmre e.g. total cellular DNA or RNA
  • Hybridization conditions resulting in particular degrees of stringency will vary depending upon the nature of the hybridization method of choice and the composition and length of the hybridizing DNA used. Generally, the temperature of hybridization and the ionic strength (especially the Na + concentration) of the hybridization buffer will determine the stringency of hybridization. Calculations regarding hybridization conditions required for attaining particular degrees of stringency are discussed by Sambrook et al. (Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, New York, 1989 chapters 9 and 11).
  • a hybridization experiment may be performed by hybridization of a DNA molecule (for example, a variant of a FGF-5 cDNA) to a target DNA molecule (for 36 -
  • Hybridization with a target probe labeled, for example, with [ 32 P]-dCTP is generally carried out in a solution of high ionic strength such as 6xSSC at a temperature that is 20-25 °C below the melting temperature, T m , described below.
  • hybridization is typically carried out for 6-8 hours using 1-2 ng/ml radiolabeled probe (of specific activity equal to 10 9 CPM/ ⁇ g or greater).
  • the nitrocellulose filter is washed to remove background hybridization. The washing conditions should be as stringent as possible to remove background hybridization but to retain a specific hybridization signal.
  • T m represents the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. Because the target sequences are generally present in excess, at T m , 50% of the probes are occupied at equilibrium.
  • T m of double-stranded DNA decreases by 1-1.5°C with every 1% decrease in homology (Bonner et al. , J. Mol. Biol. 81: 123, 1973). Therefore, for this given example, washing the filter in 0.3 xSSC at 59.4-64.4°C will produce a stringency of hybridization equivalent to 90%; that is, DNA molecules with more than 10% sequence variation relative to the target ⁇ 37 -
  • stringent conditions are those under which DNA molecules with more than 25% , 15% , 10% , 6% or 2% sequence variation (also termed "mismatch") will not hybridize. Stringent conditions are sequence dependent and are different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An example of stringent conditions is no more than about 5 °C lower than the thermal melting point T m for the specific sequence at a defined ionic strength and pH. An example of stringent conditions is a salt concentration of at least about 0.01 to 1.0 M Na ion concentration (or other salts) at pH 7.0 to 8.3 and a temperature of at least about 30°C for short probes (e.g. 10 to 50 nucleotides).
  • Stringent conditions can also be achieved with the addition of destabilizing agents such as formamide.
  • destabilizing agents such as formamide.
  • 5X SSPE 750 mM NaCl, 50 mM Na Phosphate, 5 mM EDTA, pH 7.4
  • a temperature of 25-30°C are suitable for allele-specific probe hybridizations.
  • a perfectly matched probe has a sequence perfectly complementary to a particular target sequence.
  • the test probe is typically perfectly complementary to a portion (subsequence) of the target sequence.
  • the term "mismatch probe” refers to probes whose sequence is deliberately selected not to be perfectly complementary to a particular target sequence.
  • Transcription levels can be quantitated absolutely or relatively. Absolute quantitation can be accomplished by inclusion of known concentrations of one or more target nucleic acids (for example control nucleic acids such as Bio B or with a known amount the target nucleic acids themselves) and referencing the hybridization intensity of unknowns with the known target nucleic acids (for example by generation of a standard curve).
  • target nucleic acids for example control nucleic acids such as Bio B or with a known amount the target nucleic acids themselves
  • the degeneracy of the genetic code further widens the scope of the disclosure as it enables major variations in the nucleotide sequence of a DNA molecule while maintaining the amino acid sequence of the encoded protein.
  • the eighteenth amino acid residue of FGF-5 protein is alanine.
  • This is encoded in the FGF-5 cDN A by the nucleotide codon triplet GCC.
  • three other nucleotide codon triplets, GCT, GCA and GCG also code for alanine.
  • the nucleotide sequence of the FGF-5 cDNA could be changed at this position to any of these three codons without affecting the amino acid composition of the encoded protein or the characteristics of the protein.
  • variant DNA molecules may be derived from the cDNA molecules disclosed herein using standard DNA • 38 -
  • DNA mutagenesis techmques as described above, or by synthesis of DNA sequences DNA sequences which do not hybridize under strmgent conditions to the cDNA sequences disclosed by virtue of sequence variation based on the degeneracy of the genetic code are herem also comprehended by this disclosure
  • DNA mutagenesis techmques described above may be used not only to produce variant DNA molecules, but will also facilitate the production of protems which differ m certain structural aspects from FGF-5 protems, yet which protems are clearly derivative of this protem and which maintam the essential characteristics of a FGF-5 protein as defined above
  • Newly derived protems may also be selected in order to obtam variations on the characteristic of a FGF-5 protem, as will be more fully described below
  • Such derivatives m clude those with variations m amino acid sequence including minor deletions, additions and substitutions
  • the mutation per se need not be predetermmed
  • random mutagenesis may be conducted at the target codon or region and the expressed protem variants screened for optimal activity Techmques for making substitution mutations at predetermmed sites m DNA havmg a known sequence as described above are well known
  • FGF-5 genes, cDNA, DNA molecules derived therefrom and the protem encoded by these cDNAs and derivative DNA molecules may be utilized m aspects of both the study of FGF-5 and for diagnostic and therapeutic applications related to FGF-5 Those skilled m the art will recogmze that the utilities herein described are not limited to the specific experimental modes and materials presented and will appreciate the wider potential utility of this disclosure
  • FGF-5 cDNAs SEQ ID NOS 3, 5, 7, 9, 11, 13-15, 17 and FIGS 3C and 6
  • ammo acid sequences SEQ ID NOS 4, 6, 8, 10, 12, and 16-19 and FIG 6
  • the purified protein may be used for functional analyses, antibody production and therapy in a subject as described herem
  • the DNA sequence of FGF-5 cDNAs and any variant or fragment thereof can be manipulated m studies to understand the expression of the gene and the function of its product
  • Partial or full-length cDNA sequences encodmg an FGF-5 protein may be hgated mto bacterial expression vectors Methods for expressing large amounts of protem from a cloned gene mtroduced mto E coli may be utilized for the purification, localization and functional analysis of 39 -
  • fusion proteins consisting of amino terminal peptides encoded by a portion of the _.. coli lacZ or trpE gene linked to FGF-5 may be used to prepare polyclonal and monoclonal antibodies against FGF-5. Thereafter, these antibodies may be used to purify proteins by immunoaffinity chromatography, in diagnostic assays to quantitate the levels of protein, to localize FGF-5 in tissues and individual cells by immunofluorescence and as a therapeutic to treat FGF-5 expressing or over-expressing tumors.
  • Intact native protein may also be produced in E. coli in large amounts for functional studies. Methods and plasmid vectors for producing fusion proteins and intact native proteins in bacteria are described in Sambrook et al. (Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, New York, 1989, Chapter 17, herein inco ⁇ orated by reference). Such fusion proteins may be made in large amounts, are easy to purify, and can be used to elicit antibody response. Native proteins can be produced in bacteria by placing a strong, regulated promoter and an efficient ribosome binding site upstream of the cloned gene. If low levels of protein are produced, additional steps may be taken to increase protein production; if high levels of protein are produced, purification is relatively easy.
  • Vector systems suitable for the expression of lacZ fusion genes include the pUR series of vectors (Ruther and Muller-Hill, 1983, EMBO J. 2: 1791), pEXl-3 (Stanley and Luzio, 1984, EMBO J. 3: 1429) and pMRlOO (Gray et al, 1982, Proc. Natl. Acad. Sci. USA 79:6598).
  • Vectors suitable for the production of intact native proteins include pKC30 (Shimatake and Rosenberg, 1981, Nature 292: 128), pKK177-3 (Amann and Brosius, 1985, Gene 40: 183) and pET-3 (Studiar and Moffatt, 1986, /. Mol. Biol.
  • FGF-5 fusion proteins may be isolated from protein gels, lyophilized, ground into a powder and used as an antigen.
  • the DNA sequence can also be transferred to other cloning vehicles, such as other plasmids, bacteriophages, cosmids, animal viruses and yeast artificial chromosomes (YACs) (Burke et al. , 1987, Science 236:806-12).
  • YACs yeast artificial chromosomes
  • vectors may then be introduced into a variety of hosts including somatic cells, and simple or complex organisms, such as bacteria, fungi (Timberlake and Marshall, 1989, Science 244: 1313-7), invertebrates, plants (Gasser and Fraley, 1989, Science 244: 1293), and mammals (Pursel et l. , 1989, Science 244: 1281-8), which cell or organisms are rendered transgenic by the introduction of the heterologousFGF-5 cDNA.
  • somatic cells such as bacteria, fungi (Timberlake and Marshall, 1989, Science 244: 1313-7), invertebrates, plants (Gasser and Fraley, 1989, Science 244: 1293), and mammals (Pursel et l. , 1989, Science 244: 1281-8), which cell or organisms are rendered transgenic by the introduction of the heterologousFGF-5 cDNA.
  • somatic cells such as bacteria, fungi (Timberlake and Marshall, 1989, Science 244: 1313-7
  • the cDNA sequence may be ligated to heterologous promoters, such as the simian virus SV40, promoter m the pSV2 vector (Mulligan and Berg, 1981, Proc. Natl. Acad. Sci. USA 78 2072-6), and mtroduced mto cells, such as monkey COS-1 cells (Gluzman, 1981, Cell 23.175-82), to achieve transient or long-term expression
  • the stable mtegration of the chime ⁇ c gene construct may be maintained m mammalian cells by biochemical selection, such as neomycm (Southern and Berg, 1982, J Mol. Appl. Genet. 1:327-41) and mycophoenohc acid (Mulligan and Berg, 1981, Proc. Natl. Acad. Sci. USA 78.2072-6)
  • DNA sequences can be manipulated with standard procedures such as restriction enzyme digestion, fill-in with DNA polymerase, deletion by exonuclease, extension by terminal deoxynucleotide transferase, hgation of synthetic or cloned DNA sequences, site-directed sequence- alteration via smgle-stranded bactenophage mtermediate or with the use of specific oligonucleotides m combmation with PCR.
  • standard procedures such as restriction enzyme digestion, fill-in with DNA polymerase, deletion by exonuclease, extension by terminal deoxynucleotide transferase, hgation of synthetic or cloned DNA sequences, site-directed sequence- alteration via smgle-stranded bactenophage mtermediate or with the use of specific oligonucleotides m combmation with PCR.
  • the cDNA sequence (or portions derived from it) or a mini gene (a cDNA with an mtron and its own promoter) may be mtroduced mto eukaryotic expression vectors by conventional techmques These vectors are designed to permit the transcription of the cDNA eukaryotic cells by providmg regulatory sequences that initiate and enhance the transcription of the cDNA and ensure its proper splicing and polyadenylation.
  • Vectors containing the promoter and enhancer regions of the SV40 or long termmal repeat (LTR) of the Rous Sarcoma virus and polyadenylation and splicing signal from SV40 are readily available (Mulligan and Berg, 1981, Proc Natl Acad Sci USA 78:2072-6; Gorman et al., 1982, Proc. Natl. Acad. Sci USA 78:6777-81).
  • the level of expression of the cDNA can be manipulated with this type of vector, either by using promoters that have different activities (for example, the baculovirus pAC373 can express cDNAs at high levels m S.
  • frugiperda cells (Summers and Smith, 1985, Genetically Altered Viruses and the Environment, Fields et al (Eds.) 22:319-328, Cold Sprmg Harbor Laboratory Press, Cold Sprmg Harbor, New York ) or by usmg vectors that contain promoters amenable to modulation, for example, the glucocorticoid-responsive promoter from the mouse mammary tumor virus (Lee et al. , 1982, Nature 294:228)
  • the expression of the cDNA can be momtored m the recipient cells 24 to 72 hours after introduction (transient expression)
  • vectors contain selectable markers such as the gpt (Mulligan and Berg, 1981, Proc Natl. Acad Sci. USA 78.2072-6) or neo (Southern and Berg, 1982, J. Mol. Appl Genet 1.327-41) bacterial genes These selectable markers permit selection of transfected cells that exhibit stable, long-term expression of the vectors (and therefore the cDNA)
  • the vectors can be maintained m the cells as episomal, freely replicating entities by usmg regulatory elements of viruses such as papilloma (Sarver et al , 1981, Mol Cell Biol L486) or Epstein-Barr (Sugden et al , 1985, Mol Cell Biol. 5 410) Alternatively, one can also produce cell lmes that have 41
  • the cDNA can be introduced by infection with virus vectors.
  • eukaryotic expression systems can be used for studies of FGF-5 genes and mutant forms of these genes, FGF-5 proteins and mutant forms of these proteins. Such uses include, for example, the identification of regulatory elements located in the 5' region of FGF-5 genes on genomic clones that can be isolated from genomic DNA libraries, such as human or other non- human primate libraries, using the information contained in the present disclosure.
  • the eukaryotic expression systems may also be used to study the function of the normal complete protein, specific portions of the protein, or of naturally occurring or artificially produced mutant proteins.
  • Naturally occurring mutant proteins may exist in a variety of diseases in which apoptosis has become disregulated, while artificially produced mutant proteins can be designed by site directed mutagenesis as described above. These latter studies may probe the function of any desired amino acid residue in the protein by mutating the nucleotide coding for that amino acid.
  • the expression vectors containing FGF-5 genes or cDNA sequences or variants, fragments, or mutants thereof can be introduced into human cells, mammalian cells from other species or non-mammalian cells as desired.
  • the choice of cell is determined by the pu ⁇ ose of the treatment.
  • monkey COS cells Gluzman, 1981, Cell 23: 175-82 that produce high levels of the SV40 T antigen and permit the replication of vectors containing the SV40 origin of replication may be used.
  • Chinese hamster ovary (CHO), mouse NIH 3T3 fibroblasts or human fibroblasts or lymphoblasts may be used.
  • FGF-5 polypeptides from cloned FGF-5 cDNA sequences in mammalian cells is to use the cloning vector, pXTI (Stratagene,), which contains the • 42 -
  • LTRs Long Terminal Repeats
  • GAG gene from Moloney Murine Leukemia Virus.
  • the position of the viral LTRs allows highly efficient, stable transfection of the region within the LTRs.
  • the vector also contains the He ⁇ es Simplex Thymidine Kinase promoter (TK), active in embryonal cells and in a wide-variety of tissues in mice, and a selectable neomycin gene conferring G418 resistance.
  • TK He ⁇ es Simplex Thymidine Kinase promoter
  • Two unique restriction sites Bglll and Xhol are directly downstream from the TK promoter.
  • FGF-5 cDNA including the entire open reading frame for the FGF-5 proteins and the 3' untranslated region of the cDNAs are cloned into one of the two unique restriction sites downstream from the promoter.
  • the ligated product is transfected into mouse NIH 3T3 cells using Lipofectin (Life Technologies, Inc.) under conditions outlined in the product specification. Positive transfectants are selected after growing the transfected cells in 600 ⁇ g/ml G418 (Sigma, St. Louis, MO). The protein is released into the supernatant and may be purified by standard immunoaffinity chromatography techniques using antibodies raised against FGF-5 proteins (see EXAMPLE 9).
  • FGF-5 proteins, variants, polymo ⁇ hisms, fragments of variants thereof, in eukaryotic cells can be used as a source of proteins to raise antibodies.
  • the proteins may be extracted following release of the protein into the supernatant as described above, or, the cDNA sequence may be inco ⁇ orated into a eukaryotic expression vector and expressed as a chimeric protein with, for example, ⁇ -globin.
  • Antibody to ⁇ -globin is thereafter used to purify the chimeric protein.
  • Corresponding protease cleavage sites engineered between the ⁇ -globin gene and the cDNA are then used to separate the two polypeptide fragments from one another after translation.
  • One useful expression vector for generating ⁇ -globin chimeric proteins is pSG5 (Stratagene). This vector encodes rabbit ⁇ -globin.
  • the recombinant cloning vector then comprises the selected DNA of the DNA sequences disclosed herein for expression in a suitable host.
  • the DNA is operatively linked in the vector to an expression control sequence in the recombinant DNA molecule so that the FGF-5 polypeptide can be expressed.
  • the expression control sequence may be selected from the group consisting of sequences that control the expression of genes of prokaryotic or eukaryotic cells and their viruses and combinations thereof.
  • the expression control sequence may be specifically selected from the group consisting of the lac system, the t ⁇ system, the tac system, the trc system, major operator and promoter regions of phage lambda, the control region of fd coat protein, the early and late promoters of SV40, promoters derived from polyoma, adenovirus, retrovirus, baculovirus and simian virus, the promoter for 3-phosphoglycerate kinase, the promoters of yeast acid phosphatase, the promoter of the yeast alpha-mating factors and combinations thereof.
  • the host cell which may be transfected with the vector disclosed herein, may be selected from the group consisting of bacteria, yeast, fungi, plant, insect, mouse or other animal subject; or human tissue cells.
  • mutant or variant DNA sequences similar systems are employed to express and produce the mutant or variant product.
  • This example describes several methods than can be used to produce antibodies that recognize FGF-5.
  • Such antibodies can be used to purify proteins by immunoaffmity chromatography, in diagnostic assays to quantitate FGF-5 levels, to localize FGF-5 in tissues and individual cells for example by immunofluorescence, and as a therapeutic agent to treat FGF-5 expressing or over-expressing tumors.
  • Monoclonal or polyclonal antibodies may be produced to either normal FGF-5 proteins, or variants, polymo ⁇ hisms, fragments and mutant forms thereof.
  • antibodies raised against the protein will specifically detect the protein. That is, antibodies raised against the protein (e.g. FGF-5) would recognize and bind the protein and would not substantially recognize or bind to other cellular proteins (such as serum albumin).
  • the determination that an antibody specifically detects an FGF-5 protein is made by any one of a number of standard immunoassay methods; for instance, the Western blotting technique (Sambrook et al. , 1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York).
  • a given antibody preparation (such as one produced in a mouse against the FGF-5 protein) specifically detects the FGF-5 protein by Western blotting
  • total cellular protein is extracted from cells (for example, lymphocytes) and electrophoresed on a sodium dodecyl sulfate-polyacrylamide gel.
  • the proteins are then transferred to a membrane (for example, nitrocellulose) by Western blotting, and the antibody preparation is incubated with the membrane.
  • the presence of specifically bound antibodies is detected by the use of an anti-mouse antibody conjugated to an enzyme such as alkaline phosphatase; application of the substrate 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium results in the production of a dense blue compound by immuno- localized alkaline phosphatase.
  • an enzyme such as alkaline phosphatase
  • Antibodies which specifically detect FGF-5 proteins will, by this technique, be shown to bind to the protein band, which will be localized at a given position on the gel determined by its • 44 -
  • Non-specific binding of the antibody to other proteins may occur and may be detectable as a weak signal on the Western blot.
  • the non-specific nature of this binding will be recognized by one skilled in the art by the weak signal obtained on the Western blot relative to the strong primary signal arising from the specific antibody-FGF-5 protein binding.
  • Antibodies that specifically bind to an FGF-5 protein belong to a class of molecules that are referred to herein as "specific binding agents.”
  • Specific binding agents that are capable of specifically binding to a FGF-5 protein may include polyclonal antibodies, monoclonal antibodies (including humanized monoclonal antibodies) and fragments of monoclonal antibodies such as Fab, F(ab')2 and Fv fragments, as well as any other agent capable of specifically binding to a FGF-5 protein (or the other disclosed proteins).
  • Substantially pure FGF-5 protein suitable for use as an immunogen is isolated from the transfected or transformed cells as described. Concentration of protein in the final preparation is adjusted, for example, by concentration on an Amicon filter device, to the level of a few micrograms per milliliter.
  • Monoclonal or polyclonal antibody to the protein can then be prepared as follows.
  • Monoclonal antibody to epitopes of FGF-5 proteins can be prepared from murine hybridomas according to the classical method of Kohler and Milstein (Nature 256:495, 1975) or derivative methods thereof. Briefly, a mouse is repetitively inoculated with a few micrograms of the selected protein (or epitope thereof) over a period of a few weeks. The mouse is then sacrificed, and the antibody-producing cells of the spleen isolated. The spleen cells are fused by means of polyethylene glycol with mouse myeloma cells, and the excess unfused cells destroyed by growth of the system on selective media comprising aminopterin (HAT media).
  • HAT media aminopterin
  • the successfully fused cells are diluted and aliquots of the dilution placed in wells of a microtiter plate where growth of the culture is continued.
  • Antibody-producing clones are identified by detection of antibody in the supernatant fluid of the wells by immunoassay procedures, such as ELISA, as originally described by Engvall (Enzymol. 70:419, 1980), and derivative methods thereof. Selected positive clones can be expanded and their monoclonal antibody product harvested for use. Detailed procedures for monoclonal antibody production are described in Harlow and
  • Polyclonal antiserum containing antibodies to heterogeneous epitopes of a single protein can be prepared by immunizing suitable animals with the expressed protein, which can be unmodified or modified to enhance immunogenicity. Effective polyclonal antibody production is affected by many factors related both to the antigen and the host species. For example, small molecules tend to be less immunogenic than others and may require the use of carriers and adjuvant. Also, host animals vary in response to site of inoculations and dose, with both inadequate or excessive doses of antigen resulting in low titer antisera. Small doses (ng level) of antigen administered at multiple intradermal sites appears to be most reliable. An effective immunization protocol for rabbits can be found in Vaitukaitis et al. (J. Clin. Endocrinol. Metab. 33:988-91, 1971).
  • Booster injections can be given at regular intervals, and antiserum harvested when antibody titer thereof, as determined semi-quantitatively, for example, by double immunodiffusion in agar against known concentrations of the antigen, begins to fall. See, for example, Ouchterlony et al. (In: Handbook of Experimental Immunology, Wier, D. (ed.). Chapter 19. Blackwell. 1973). Plateau concentration of antibody is usually in the range of 0.1 to 0.2 mg/ml of serum (about 12 ⁇ M). Affinity of the antisera for the antigen is determined by preparing competitive binding curves, as described, for example, by Fisher (Manual of Clinical Immunology, Chapter 42. 1980).
  • Another approach to raising antibodies against FGF-5 proteins is to use synthetic peptides synthesized on a commercially available peptide synthesizer based upon the predicted amino acid sequence of FGF-5 proteins.
  • Antibodies may be raised against FGF-5 proteins by subcutaneous injection of a DNA vector which expresses a FGF-5 protein into laboratory animals, such as mice. Delivery of the recombinant vector into the animals may be achieved using a hand-held form of the Biolistic system (Sanford et al. , 1987, Pariculate Sci. Technol. 5:27-37) as described by Tang et al. (Nature, 356: 152-4, 1992).
  • Expression vectors suitable for this pu ⁇ ose may include those which express a FGF-5 cDNA under the transcriptional control of either the human actin promoter or the cytomegalovirus (CMV) promoter.
  • CMV cytomegalovirus
  • Antibody preparations prepared according to these protocols are useful in quantitative immunoassays which determine concentrations of antigen-bearing substances in biological samples; - 46 -
  • Antibodies Raised by Injection of FGF-5 cDNA Antibodies may be raised against FGF-5 proteins by subcutaneous injection of a DNA vector which expresses FGF-5 protein (or variant, fragment, polymo ⁇ hism, or mutant thereof) into laboratory animals, such as mice. Delivery of the recombinant vector into the animals may be achieved using a hand-held form of the Biolistic system (Sanford et al. , Paniculate Sci. Technol. 5:27-37, 1987) as described by Tang et al. (Nature 356: 152-4, 1992). Expression vectors suitable for this pu ⁇ ose may include those which express the FGF-5 cDNA under the transcriptional control of either the human ⁇ -actin promoter or the CMV promoter.
  • Antibody preparations prepared according to these protocols are useful in quantitative immunoassays which determine concentrations of antigen-bearing substances in biological samples; they are also used semi-quantitatively or qualitatively to identify the presence of antigen in a biological sample.
  • Antibodies disclosed herein can be conjugated with various labels for their direct detection (see Chapter 9, Harlow and Lane, Antibodies: A Laboratory Manual. 1988).
  • the label which may include, but is not limited to, a radiolabel, enzyme, fluorescent probe, or biotin, is chosen based on the method of detection available to the user.
  • Antibodies can be radiolabeled with iodine ( 125 I), which yields low-energy gamma and X- ray radiation.
  • iodine 125 I
  • 10 ⁇ g of protein in 25 ⁇ l of 0.5 M sodium phosphate (pH 7.50 is placed in a 1.5 ml conical tube.
  • 500 ⁇ C of Na ,25 I, and 25 ⁇ l of 2 mg/ml chloramine T is added and incubated for 60 seconds at RT.
  • 50 ⁇ l of chloramine T stop buffer is added (2.4 mg/ml sodium metabisulfite, 10 mg/ml tyrosine, 10% glycerol, 0.1 % xylene cyanol in PBS).
  • the iodinated antibody is separated from the iodotyrosine on a gel filtration column.
  • Antibodies disclosed herein can also be labeled with biotin, with enzymes such as alkaline phosphatase (AP) or horseradish peroxidase (HRP) or with fluorescent dyes. The method of producing these conjugates is determined by the reactive group on the label added.
  • the antibodies described above can be used to treat FGF-5 expressing or overexpressing tumors, for example by decreasing FGF-5 activity. Assays to determine whether an antibody modulates the immune response are described in EXAMPLES 2-4. Antibodies which recognize ⁇ 47 -
  • FGF-5 may cause regression of an FGF-5 expressmg or overexpressing tumor
  • antibodies can be used as diagnostic agents, for example to momtor the progression or regression of an FGF-5 expressmg or over expressing tumor in a subject, for example a subject undergoing therapy to treat the neoplasim
  • EXAMPLE 10 Diagnostic Methods One embodiment disclosed herein is a method of pre-screening cells, such as tumor cells to determme if the cells express or over-express FGF-5, and if the subject is HLA-A3 + This can be determmed by conventional methods for identifying cells which present a particular HLA molecule, and identifying cells expressing DNA of the pertinent sequences, m this case a FGF-5 sequence
  • cells presenting the relevant HLA complex are identified via the foregomg screening methodology, they can be combmed with a sample from a subject, where the sample contams CTLs If the complex-presentmg cells are lysed by the mixed CTL sample, then it can be assumed that a FGF-5 TAA is being presented, and the subject is an appropriate candidate for the therapeutic approaches set forth herem
  • a subject can be screened to determme if the cells of a subject carry an FGF-5 gene, for example a wild-type FGF-5 gene, polymo ⁇ hic, mutant or variant FGF-5 genes havmg a heterozygous or homozygous nucleotide change, or insertions, partial deletion, or duplications of the FGF-5 gene
  • FGF-5 sequence information presented herem is m the area of genetic testmg for predisposition to disease, such as cancer, owmg to the presence and expression or overexpression of an FGF-5 gene
  • Predisposition to other diseases, mcludmg but not limited to Hippel-Lindau disease, horseshoe kidneys, adult polycystic kidney disease, and acquired renal cystic disease, owing to the presence and expression or overexpression of an FGF-5 gene, can also be determmed usmg the methods disclosed herem
  • the sequence of FGF-5 genes is also useful m such diagnostic methods
  • the method consists of providing a biological sample obtained from the subject, m which sample mcludes DNA or RNA, and providmg an assay for detectmg m the biological sample the presence, absence, variant, or mutation of a FGF-5 gene and FGF-5 RNA
  • Suitable biological samples mclude samples obtained from body cells, such as those present m peripheral blood, reiterate, saliva, tissue biopsy, surgical specimen, fine needle aspirate specimen, amniocentesis samples and autopsy material
  • the detection m the biological sample may be performed by a number of methodologies, as outlined below
  • the foregomg assay may be assembled m the form of a diagnostic kit and may mclude, for example, hybridization with oligonucleotides, PCR amplification of the gene or a part thereof usmg ⁇ 48
  • oligonucleotide primers RT-PCR amplification of the RNA or a part thereof using oligonucleotide primers; or direct sequencing of an FGF-5 gene of the subject's genome using oligonucleotide primers.
  • the efficiency of these molecular genetic methods should permit a rapid classification of patients affected by the presence of one or more copies of an FGF-5 gene, or deletions, variants, polymo ⁇ hisms or mutations of a FGF-5 gene.
  • RNA isolation techniques is the PCR amplification of reverse transcribed RNA (RT-PCR) of RNA isolated from cells (for example cells from a tumor) followed by direct DNA sequence determination of the products.
  • RT-PCR reverse transcribed RNA
  • the presence of one or more nucleotide differences between the obtained sequence and the cDNA sequences, and especially, differences in the ORF portion of the nucleotide sequence are taken as indicative of a potential FGF-5 gene mutation.
  • DNA extracted from tumor or other cells may be used directly for amplification.
  • the direct amplification from genomic DNA would be appropriate for analysis of the entire FGF-5 gene including regulatory sequences located upstream and downstream from the open reading frame. Reviews of direct DNA diagnosis have been presented by Caskey (Science 236: 1223-8, 1989) and by Landegren et al. (Science 242:229-37 , 1989).
  • FGF-5 genes isolated from subjects may reveal particular mutations, duplications, variants, polymo ⁇ hisms, or deletions, which occur at a high frequency within this population of individuals.
  • DNA diagnostic methods it is possible to design DNA diagnostic methods to specifically detect the most common FGF-5 mutations, variants, polymo ⁇ hisms, or deletions.
  • the detection of specific DNA mutations may be achieved by methods such as hybridization using specific oligonucleotides (Wallace et al. , 1986, Cold Spring Harbor Symp. Quant. Biol. 51 :257-61), direct DNA sequencing (Church and Gilbert, 1984, Proc. Natl. Acad. Sci. USA. 81 : 1991-5), the use of restriction enzymes (Flavell et al , 1978, Cell 15:25; Geever et al. , 1981, Proc. Natl. Acad. Sci USA 78:5081), discrimination on the basis of electrophoretic mobility in gels with denaturing reagent (Myers and Maniatis, 1986, Cold Spring Harbor Symp. Quant. Biol.
  • Oligonucleotides specific to normal, variant, polymo ⁇ hic, or mutant sequences are chemically synthesized using commercially available machines, labeled radioactively with isotopes (such as 32 P) or non-radioactively, with tags such as biotin (Ward and Langer et al. , 1981, Proc. Natl. Acad. Sci. USA 78:6633-57), and hybridized to individual DNA samples immobilized on membranes or other solid supports by dot-blot or transfer from gels after electrophoresis.
  • Genetic testing based on DNA sequence differences can be achieved by detection of alteration in electrophoretic mobility of DNA fragments in gels with or without denaturing reagent. Small sequence deletions and insertions can be visualized by high-resolution gel electrophoresis.
  • a PCR product with small deletions is clearly distinguishable from a normal sequence on an 8% non-denaturing polyacrylamide gel (WO 91/10734; Nagamine et al. , 1989, Am. J. Hum. Genet. 45:337-9).
  • DNA fragments of different sequence compositions may be distinguished on denaturing formamide gradient gels in which the mobilities of different DNA fragments are retarded in the gel at different positions according to their specific "partial-melting" temperatures (Myers et al., 1985, Science 230:1242).
  • a method of detecting a mutation comprising a single base substitution or other small change could be based on differential primer length in a PCR.
  • an invariant primer could be used in addition to a primer specific for a mutation.
  • the PCR products of the normal and mutant genes can then be differentially detected in acrylamide gels. 50 -
  • DNA fragments may also be visualized by methods where the individual DNA samples are not immobilized on membranes.
  • the probe and target sequences may be both in solution, or the probe sequence may be immobilized (Saiki et al. , 1989, Proc. Nat. Acad. Sci. USA 86:6230-4).
  • a variety of detection methods such as autoradiography involving radioisotopes, direct detection of radioactive decay (in the presence or absence of scintillant), spectrophotometry involving calorigenic reactions and fluorometry involved fluorogenic reactions, may be used to identify specific individual genotypes.
  • a system capable of detecting such multiple mutations is desirable.
  • a PCR with multiple, specific oligonucleotide primers and hybridization probes may be used to identify all possible mutations at the same time (Chamberlain et al., 1988, Nucl. Acids Res. 16: 1141-55).
  • the procedure may involve immobilized sequence-specific oligonucleotides probes (Saiki et al., 1989, Proc. Nat. Acad. Sci. USA 86:6230-4).
  • oligonucleotide arrays also known as "DNA chips” as described by Hacia et al. (Nat. Genet. 14:441-7, 1996).
  • a tissue sample from a subject can be processed according to the method disclosed by Antonarakis et al. (New Eng. J. Med. 313:842-848, 1985), separated through a 1 % agarose gel and transferred to a nylon membrane for Southern blot analysis.
  • Membranes are UV cross linked at 150 ml using a GS Gene Linker (Bio-Rad, Hercules, CA).
  • An FGF-5 probe is subcloned into pTZ18U.
  • the phagemids can be transformed into E. coli MV 1190 infected with M13K07 helper phage (Bio-Rad, Richmond, Calif.). Single stranded DNA is isolated according to standard procedures (Sambrook, et al. Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, New York, 1989).
  • Blots are prehybridized for 15-30 minutes at 65 °C in 7% sodium dodecyl sulfate (SDS) in 0.5 M NaP0 4 .
  • SDS sodium dodecyl sulfate
  • the methods follow those described by Nguyen, et al. (BioTechniques 13: 116-123, 1992).
  • the blots are hybridized overnight at 65 °C in 7% SDS, 0.5 M NaP0 4 with 25-50 ng/ml single stranded probe DNA.
  • Post-hybridization washes consist of two 30 minute washes in 5% SDS, 40 mM NaP0 4 at 65°C, followed by two 30-minute washes in 1 % SDS, 40 mM NaP0 4 at 65 °C. 51
  • the blots are subsequently rinsed with phosphate buffered saline (pH 6.8) for five minutes at RT and incubated with 0.2% casein in PBS for five minutes.
  • the blots are then preincubated for 5-10 minutes in a shaking water bath at 45 °C with hybridization buffer consisting of 6 M urea, 0.3 M NaCl, and 5X Denhardt's solution (see Sambrook, et al. , Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, New York, 1989).
  • the buffer is removed and replaced with 50-75 ⁇ l/cm 2 fresh hybridization buffer plus 2.5 nM of the covalently cross-linked oligonucleotide sequence complementary to the universal primer site (UP-AP, Bio-Rad).
  • the blots are hybridized for 20-30 minutes at 45 °C and post hybridization washes are incubated at 45 °C as two 10 minute washes in 6 M urea, IX standard saline citrate (SSC), 0.1 % SDS and one 10 minute wash in 1XSSC, 0.1 % TritonTMX-100.
  • the blots are rinsed for 10 minutes at RT with lXSSC.
  • Blots are incubated for 10 minutes at RT with shaking in the substrate buffer consisting of 0.1 M diethanolarnine, 1 mM MgCl 2 , 0.02% sodium azide, pH 10.0.
  • Individual blots are placed in heat sealable bags with substrate buffer and 0.2 mM AMPPD (3-(2'-spiroadamantane)-4-methoxy- 4-(3'-phosphoryloxy)phenyl-l,2-dioxetane, disodium salt, Bio-Rad). After a 20 minute incubation at RT with shaking, the excess AMPPD solution is removed. The blot is exposed to X-ray film overnight. Patient samples which show no hybridizing bands lack a FGF-5 gene.
  • Patient samples which show positive bands indicate the presence of at least one copy of an FGF-5 gene, possibly more, which would indicate the possibility of ongoing disease such as cancer, such as RCC, prostate or breast cancer, or an enhanced susceptibility to developing a disease, such as cancer, in the future.
  • the method involves assaying for the presence of transcription factors which may modulate expression of FGF-5.
  • Patient samples which show positive bands for the transcription factor indicate the presence of at least one copy of the transcription factor gene, possibly more, which would indicate the possibility of ongoing disease such as cancer, such as RCC, prostate or breast cancer, or an enhanced susceptibility to developing a disease, such as cancer, in the future.
  • EXAMPLE 12 Quantitation of FGF-5 Proteins An alternative method of diagnosing the presence of an FGF-5 and/or transcription factor gene is to quantitate the level of FGF-5 protein in the cells of a subject. This diagnostic tool is useful for detecting elevated levels of FGF-5 protein which result from, for example, expression or overexpression ol the FGF-5 gene, the presence of multiple copies of an FGF-5 and/or transcription factor(s) gene, or mutations (such as mutations within the gene, or mutations upstream or downstream from the gene which affect its expression) which result in increased expression of - 52 -
  • FGF-5 FGF-5.
  • These diagnostic methods in addition to those described in EXAMPLES 10 and 11, provide an enhanced ability to diagnose susceptibility to diseases caused by FGF-5 expression or overexpression.
  • the determination of elevated FGF-5 protein levels is an alternative or supplemental approach to the direct determination of whether the FGF-5 gene (or transcription factor gene(s)) is present in multiple copies or if mutations are present (for example mutations up- or down-stream of an FGF-5 gene) that would result in increased FGF-5 expression, using the methods outlined above in EXAMPLES 10 and 11.
  • the availability of antibodies specific to the FGF-5 protein will facilitate the quantitation of cellular FGF-5 protein by one of a number of immunoassay methods which are well known in the art and are presented in Harlow and Lane (Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, New York. 1988).
  • Such assays permit both the detection of FGF-5 proteins in a biological sample and the quantitation of such proteins.
  • Typical methods involve providing a biological sample of the subject in which the sample contains cellular proteins, and providing an immunoassay for quantitating the level of FGF-5 protein in the biological sample. This can be achieved by combining the biological sample with a FGF-5 specific binding agent, such as an anti-FGF-5 antibody (such as monoclonal or polyclonal antibodies), so that complexes form between the binding agent and the FGF-5 protein present in the sample, and then detecting or quantitating such complexes.
  • a FGF-5 specific binding agent such as an anti-FGF-5 antibody (such as monoclonal or polyclonal antibodies)
  • these assays may be performed with the FGF-5 specific binding agent immobilized on a support surface, such as in the wells of a microtiter plate or on a column.
  • the biological sample is then introduced onto the support surface and allowed to interact with the specific binding agent so as to form complexes. Excess biological sample is then removed by washing, and the complexes are detected with a reagent, such as a second anti-FGF-5 protein antibody that is conjugated with a detectable marker.
  • the cellular proteins are isolated and subjected to SDS-PAGE followed by Western blotting. After resolving the proteins, the proteins are transferred to a membrane, which is probed with specific binding agents that recognize FGF-5. The proteins are detected, for example with HRP-conjugated secondary antibodies, and quantitated.
  • the level of FGF-5 protein in cells is analyzed using microscopy.
  • samples can be analyzed for the presence of FGF-5 proteins. For example, frozen biopsied tissue sections are thawed at room temperature and fixed with acetone at -200 °C for five minutes. Slides are washed twice in cold PBS for five minutes each, then air-dried. Sections are covered with 20-30 ⁇ l of antibody solution (15-45 ⁇ g/ml) (diluted in PBS, 2% BSA at 15-50 ⁇ g/ml) and incubated at RT in a humidified chamber for - 53 -
  • Slides are washed three times with cold PBS five minutes each, allowed to air-dry briefly (5 minutes) before applying 20-30 ⁇ l of the second antibody solution (diluted in PBS, 2% BSA at 15-50 ⁇ g/ml) and incubated at RT in humidified chamber for 30 minutes.
  • the label on the second antibody may contain a fluorescent probe, enzyme, radiolabel, biotin, or other detectable marker.
  • the slides are washed three times with cold PBS five minutes each then quickly dipped in distilled water, air-dried, and mounted with PBS containing 30% glycerol. Slides can be stored at 4°C prior to viewing.
  • the second antibody is conjugated to gold particles.
  • Tissue is fixed and embedded with epoxy plastics, then cut into very thin sections ( " 1-2 ⁇ m).
  • the specimen is then applied to a metal grid, which is then incubated in the primary anti-FGF-5 antibody, washed in a buffer containing BSA, then incubated in a secondary antibody conjugated to gold particles (usually 5-20 nm). These gold particles are visualized using electron microscopy methods.
  • a "control" sample of the subject which sample does not express FGF-5 or expresses FGF-5 at lower levels, can be used to compare FGF-5 expression in the sample to be analyzed.
  • Such a "control" sample may be obtained from normal adult cells, such as those present in which expression of the protein is not detected. As shown in FIG. 4, for example, FGF-5 is not expressed in detectable levels in any normal tissue tested.
  • peripheral blood leukocytes is clearly the most accessible and convenient source from which comparative samples can be obtained. Sample specimens can be obtained from peripheral blood, urine, saliva, tissue biopsy, amniocentesis samples, surgical specimens, fine needle aspirates, and autopsy material, particularly cancer cells.
  • Quantitation of FGF-5 proteins can be made by immunoassay and compared to levels of the protein found in non- FGF-5 expressing cells, such as normal adult tissues, or to the level of FGF-5 in healthy, normal cells (for example, cells of the same origin that are not neoplastic or are free of the disease of interest).
  • a significant (for example 50% or greater) increase in the amount of FGF-5 protein in the cells of a subject compared to the amount of FGF-5 protein found in non-FGF-5 expressing cells or that found in normal cells, would be taken as an indication that the presence of the FGF-5 gene locus in the subject.
  • EXAMPLE 13 Gene Therapy A new gene therapy approach for subjects suffering from tumors which express or over- express FGF-5 is now made possible by the present disclosure. Administration of FGF-5 to a subject suffering from a tumor that expresses or over-expresses FGF-5, may further enhance the 54 -
  • modulation of the immune response such as stimulatmg CTLs to lyse the FGF-5 expressmg mmor cells, and achieve the desired therapeutic goal of assisting m regression of the tumor
  • expression or overexpression of FGF-5 by the mmor may be insufficient to stimulate the immune system, for example in non HLA-A3 subjects
  • modulation of the immune response may be augmented by additional FGF-5 expression
  • cells may be removed from a subject, such as dendritic cells, suffermg from a tumor that expresses or over-expresses FGF-5, and then transfected with an expression vector contaming FGF-5 cDNA These transfected cells will thereby produce functional FGF-5 protem and can be remtroduced into the subject to stimulate CTLs
  • the scientific and medical procedures required for human cell transfection are now routme procedures
  • the provision herein of FGF-5 cDNAs now allows the development of human gene therapy based upon these procedures Immunotherapy of melanoma patients using genetically
  • a method of treatmg tumors which express or overexpress FGF-5, or m which greater FGF-5 expression is desired is disclosed These methods can be accomplished by mtroducing a gene codmg for FGF-5 mto a subject
  • a general strategy for transferring genes mto donor cells is disclosed m U S Patent No 5,529,774
  • a gene encodmg a protem havmg therapeutically desired effects is cloned into a viral expression vector, and that vector is then mtroduced mto the target organism
  • the virus mfects the cells, and produces the protem sequence in vivo, where it has its desired therapeutic effect See, for example, Zabner et al (Cell 75 207- 16, 1993)
  • it may only be necessary to mtroduce the genetic or protem elements mto certain cells or tissues For example, m the case of benign nevi and psoriasis, m
  • the recombinant nucleic acid can be administered to the subject by any method which allows the recombinant nucleic acid to reach the appropriate cells. These methods include injection, infusion, deposition, implantation, or topical administration. Injections can be intradermal or subcutaneous.
  • the recombinant nucleic acid can be delivered as part of a viral vector, such as avipox viruses, recombinant vaccinia virus, replication-deficient adenovirus strains or poliovirus, or as a non-infectious form such as naked DNA or liposome encapsulated DNA.
  • Adenoviral vectors may include essentially the complete adenoviral genome (Shenk et al. , Curr. Top. Microbiol. Immunol. 111: 1-39, 1984).
  • the adenoviral vector may be a modified adenoviral vector in which at least a portion of the adenoviral genome has been deleted.
  • the vector includes an adenoviral 5' ITR; an adenoviral 3' ITR; an adenoviral encapsidation signal; a DNA sequence encoding a therapeutic agent; and a promoter for expressing the DNA sequence encoding a therapeutic agent.
  • the vector is free of at least the majority of adenoviral El and E3 DNA sequences, but is not necessarily free of all of the E2 and E4 DNA sequences, and DNA sequences encoding adenoviral proteins transcribed by the adenoviral major late promoter.
  • the vector may be an adeno-associated virus (AAV) such as described in U.S. Patent No. 4,797,368 (Carter et al.) and in McLaughlin et al. (J. Virol. 62: 1963- 73, 1988) and AAV type 4 (Chiorini et al. J. Virol. 71:6823-33, 1997) and AAV type 5 (Chiorini et al. J. Virol. 73: 1309-19, 1999).
  • AAV adeno-associated virus
  • Such a vector may be constructed according to standard techmques, using a shuttle plasmid which contains, beginning at the 5' end, an adenoviral 5' ITR, an adenoviral encapsidation signal, and an Ela enhancer sequence; a promoter (which may be an adenoviral promoter or a foreign promoter); a tripartite leader sequence, a multiple cloning site (which may be as herein described); a poly A signal; and a DNA segment which corresponds to a segment of the adenoviral genome.
  • a shuttle plasmid which contains, beginning at the 5' end, an adenoviral 5' ITR, an adenoviral encapsidation signal, and an Ela enhancer sequence; a promoter (which may be an adenoviral promoter or a foreign promoter); a tripartite leader sequence, a multiple cloning site (which may be as herein described); a poly A signal; and a DNA
  • the DNA segment serves as a substrate for homologous recombination with a modified or mutated adenovirus, and may encompass, for example, a segment of the adenovirus 5' genome no longer than from base 3329 to base 6246.
  • the plasmid may also include a selectable marker and an origin of replication.
  • the origin of replication may be a bacterial origin of replication.
  • a desired DNA sequence encoding a therapeutic agent may be inserted into the multiple cloning site of the plasmid.
  • the plasmid may be used to produce an adenoviral vector by homologous recombination with a modified or mutated adenovirus in which at least the majority of the El and E3 adenoviral 56 -
  • Homologous recombination may be effected through co- transfection of the plasmid vector and the modified adenovirus into a helper cell line, such as 293 cells, by CaP0 4 precipitation.
  • the homologous recombination produces a recombinant adenoviral vector which includes DNA sequences derived from the shuttle plasmid between the Not I site and the homologous recombination fragment, and DNA derived from the El and E3 deleted adenovirus between the homologous recombination fragment and the 3 ' ITR.
  • the adenovirus may be constructed by using a yeast artificial chromosome (or YAC) containing an adenoviral genome according to the method described in Ketner et al. (Proc. Natl. Acad. Sci. USA, 91:6186-90, 1994), in conjunction with the teachings contained herein.
  • the adenovirus yeast artificial chromosome is produced by homologous recombination in vivo between adenoviral DNA and yeast artificial chromosome plasmid vectors carrying segments of the adenoviral left and right genomic termini.
  • a DNA sequence encoding a therapeutic agent then may be cloned into the adenoviral DNA.
  • the modified adenoviral genome then is excised from the adenovirus yeast artificial chromosome in order to be used to generate adenoviral vector particles as hereinabove described.
  • the adenoviral particles are admmistered in an amount effective to produce a therapeutic effect in a subject.
  • the exact dosage of adenoviral particles to be administered is dependent upon a variety of factors, including the age, weight, and sex of the subject to be treated, and the namre and extent of the disease or disorder to be treated.
  • the adenoviral particles may be administered as part of a preparation having a titer of adenoviral particles of at least 1 x 10 10 pfu/ml, and in general not exceeding 2 x 10" pfu/ml.
  • the adenoviral particles may be administered in combination with a pharmaceutically acceptable carrier in a volume up to 10 ml.
  • the pharmaceutically acceptable carrier may be, for example, a liquid carrier such as a saline solution, protamine sulfate (Elkins- Sinn, Inc. , Cherry Hill, NJ), or Polybrene (Sigma Chemical) as well as those described in EXAMPLE 18.
  • a liquid carrier such as a saline solution, protamine sulfate (Elkins- Sinn, Inc. , Cherry Hill, NJ), or Polybrene (Sigma Chemical) as well as those described in EXAMPLE 18.
  • the viral vector is a retroviral vector.
  • Retroviruses have been considered for experiments in gene therapy because they have a high efficiency of infection and stable integration and expression (Orkin et al. , 1988, Prog. Med. Genet.7: 130-42). Partial or full length FGF-5 genes can be cloned into a retroviral vector and driven from either its endogenous promoter or from the retroviral LTR (long terminal repeat).
  • retroviral vectors which may be employed include, but are not limited to, Moloney Murine Leukemia Virus, spleen necrosis virus, and vectors derived from retroviruses such as Rous Sarcoma Virus, Harvey Sarcoma Virus, avian leukosis virus, human immunodeficiency virus, myeloproliferative sarcoma virus, and mammary mmor virus.
  • the vector is generally a replication defective retrovirus particle. 57 -
  • Retroviral vectors are useful as agents to effect retroviral-mediated gene transfer into eukaryotic cells.
  • Retroviral vectors are generally constructed such that the majority of sequences coding for the structural genes of the virus are deleted and replaced by the gene(s) of interest. Most often, the structural genes (i.e. , gag, pol, and env) are removed from the retroviral backbone using genetic engineering techniques known in the art. This may include digestion with the appropriate restriction endonuclease or, in some instances, with Bal 31 exonuclease to generate fragments containing appropriate portions of the packaging signal.
  • Vaccinia virus Moss et al. , 1987, Annu. Rev. Immunol. 5:305-24
  • Bovine Papilloma virus Rosmussen et al. , 1987, Methods Enzymol. 139:642-54
  • members of the he ⁇ es virus group such as Epstein-Barr virus (Margolskee et al., 1988, Mol. Cell. Biol. 8:2837-47).
  • Epstein-Barr virus Margolskee et al., 1988, Mol. Cell. Biol. 8:2837-47
  • Recent developments in gene therapy techniques include the use of RNA-DNA hybrid oligonucleotides, as described by Cole-Strauss et al. (Science 273: 1386-9, 1996).
  • Retroviral vectors have also been constructed which can introduce more than one gene into target cells. Usually, in such vectors one gene is under the regulatory control of the viral LTR, while the second gene is expressed either off a spliced message or is under the regulation of its own, internal promoter. Alternatively, two genes may be expressed from a single promoter by the use of an Internal Ribosome Entry Site.
  • the present disclosure includes biologically active molecules that mimic the action (mimetics) of the FGF-5 proteins disclosed herein.
  • the disclosure therefore includes synthetic embodiments of naturally-occurring peptides, as well as analogues (non-peptide organic molecules), derivatives (chemically functionalized peptide molecules obtained starting with the disclosed peptide sequences) and variants (homologs) of these peptides that stimulate an HLA-A3-restricted CTL immune response against FGF-5 expressing or over-expressing tumors, as measured by IFN- ⁇ concentration.
  • Each peptide ligand disclosed is comprised of a sequence of amino acids, which may be either L- and/or D- amino acids, namrally occurring and otherwise.
  • Peptides may be modified by a variety of chemical techniques to produce derivatives having essentially the same activity as the unmodified peptides, and optionally having other 58 -
  • carboxylic acid groups of the peptide may be provided in the form of a salt of a pharmaceutically-acceptable cation or esterified to form a C1-C16 ester, or converted to an amide of formula NR1R2 wherein Rl and R2 are each independently H or C1-C16 alkyl, or combined to form a heterocyclic ring, such as a 5- or 6- membered ring.
  • Amino groups of the peptide may be in the form of a pharmaceutically-acceptable acid addition salt, such as the HCl, HBr, acetic, benzoic, toluene sulfonic, maleic, tartaric and other organic salts, or may be modified to C1-C16 alkyl or dialkyl amino or further converted to an amide.
  • a pharmaceutically-acceptable acid addition salt such as the HCl, HBr, acetic, benzoic, toluene sulfonic, maleic, tartaric and other organic salts
  • Hydroxyl groups of the peptide side chain may be converted to C1-C16 alkoxy or to a Cl- C16 ester using well-recognized techniques.
  • Phenyl and phenolic rings of the peptide side chain may be substituted with one or more halogen atoms, such as fluorine, chlorine, bromine or iodine, or with C1-C16 alkyl, C1-C16 alkoxy, carboxylic acids and esters thereof, or amides of such carboxylic acids.
  • Methylene groups of the peptide sidechains can be extended to homologous C2- C4 alkylenes. Thiols can be protected with any one of a number of well-recognized protecting groups, such as acetamide groups.
  • cyclic strucmres into the peptides disclosed herein to select and provide conformational constraints to the structure that result in enhanced stability.
  • a carboxyl-terminal or amino-terminal cysteine residue can be added to the peptide, so that when oxidized the peptide will contain a disulfide bond, thereby generating a cyclic peptide.
  • Other peptide cyclizing methods include the formation of thioethers and carboxyl- and amino-terminal amides and esters.
  • particular peptide variants will differ by only a small number of amino acids from the peptides disclosed herein.
  • Such variants may have deletions (for example of 1-3 or more amino acid residues), insertions (for example of 1-3 or more residues), or substitutions that do not interfere with the desired activity of the peptides.
  • Substitutional variants are those in which at least one residue in the amino acid sequence has been removed and a different residue inserted in its place.
  • such variants will have amino acid substitutions of single residues, for example 1 , 3, 5 or even 10 substitutions in the FGF-5 protein (SEQ ID NOS: 4, 6, 8, 10, 12, and 16-19).
  • Peptidomimetic and organomimetic embodiments are also disclosed, whereby the three- dimensional arrangement of the chemical constituents of such peptido- and organomimetics mimic the three-dimensional arrangement of the peptide backbone and component amino acid side chains in the peptide, resulting in such peptido- and organomimetics of the peptides having the ability to modulate an immune response against FGF-5 expressing or over-expressing tumors, as measured by IFN- ⁇ concentration (FGF-5 mimetics).
  • FGF-5 mimetics IFN- ⁇ concentration
  • Peptido- and organomimetics can be designed to fit each pharmacophore with current computer modeling software (using computer assisted drug design or CADD). See Walters, "Computer- Assisted Modeling of Drugs", in Klegerman & Groves, eds., 1993, Pharmaceutical Biotechnology, Inte ⁇ harm Press: Buffalo Grove, IL, pp. 165-174 and Principles of Pharmacology (ed. Munson, 1995), chapter 102 for a description of techniques used in CADD. Also disclosed are mimetics prepared using such techniques that produce either peptides or conventional organic pharmaceuticals that retain the ability to modulate an immune response or modulate FGF-5 expression or activity.
  • the above described mimetics are examined for their ability to stimulate an HLA-A3- restricted CTL immune response against FGF-5 expressing or over-expressing tumors, as measured by IFN- ⁇ concentration. Such activities can be readily determined using the assays disclosed herein, for example using the methods described in EXAMPLES 2-4. Suitable mimetics would demonstrate the ability to modulate an immune response or modulate FGF-5 expression or activity as defined above.
  • EXAMPLE 16 Methods for Generating Mimetics
  • compounds or other molecules which mimic normal FGF-5 function such as compounds which modulate an immune response or modulate FGF-5 expression or activity, for example modulate an immune response against FGF-5 expressing or over-expressing tumors, as measured by IFN- ⁇ concentration, can be identified and/or designed. These compounds or molecules are known as mimetics, because they mimic the biological activity of the normal protein.
  • FGF-5 is co-crystallized in the presence of the MHC.
  • One method that can be used is the hanging drop method. In this method, a concentrated salt, the FGF-5 protein and the MHC protein solution is applied to the underside of a lid of a multiwell dish. A range of concentrations may need to be tested. The lid is placed onto the dish, such that the droplet "hangs" from the lid. As the solvent evaporates, a protein crystal is formed, which can be visualized with a microscope.
  • This crystallized structure is then subjected to X-ray diffraction or NMR analysis which allows for the identification of the amino acid residues that are in contact with one another.
  • the amino acids that contact the transcription factors establish a pharmacophore that can then be used to identify drugs that interact at that same site.
  • synthetic peptides can be designed from the sequence of the MHC that interacts with FGF-5. Several different peptides could be generated from this region(s). This could be done with or without the crystallography data. However, once crystallography data is available, peptides can also be designed that bind better than FGF-5.
  • the chimeric peptides may be expressed recombinantly, for example in E. coli.
  • One advantage of the synthetic peptides over the monoclonal antibodies is that they are smaller, and therefore diffuse easier, and are not as likely to be immunogenic. Standard mutagenesis of such peptides can also be performed to identify variant peptides having even greater ability to modulate an immune response or modulate FGF-5 expression or activity as defined herein.
  • the disclosed peptides can be chemically synthesized by any of a number of manual or automated methods of synthesis known in the art.
  • solid phase peptide synthesis SPPS
  • SPPS solid phase peptide synthesis
  • mmole millimole
  • Fmoc 9-fluorenylmethyloxycarbonyl
  • HMP p-hydroxymethylphenoxymethylpolystyrene
  • Sasrin resin for carboxyl-terminus acids
  • Rink amide resin for carboxyl-terminus amides.
  • Fmoc-derivatized amino acids are prepared from the appropriate precursor amino acids by tritylation and triphenylmethanol in trifluoroacetic acid, followed by Fmoc derivitization as described by Atherton et al. (Solid Phase Peptide Synthesis, IRL Press: Oxford, 1989).
  • Sasrin resin-bound peptides are cleaved using a solution of 1 % TFA in dichloromethane to yield the protected peptide.
  • protected peptide precursors are cyclized between the amino- and carboxyl-termini by reaction of the amino-terminal free amine and carboxyl- terminal free acid using diphenylphosphorylazide in nascent peptides wherein the amino acid sidechains are protected.
  • HMP or Rink amide resin-bound products are routinely cleaved and protected sidechain- containing cyclized peptides deprotected using a solution comprised of trifluoroacetic acid (TFA), optionally also comprising water, thioanisole, and ethanedithiol, in ratios of 100 : 5 : 5 : 2.5, for 0.5 - 3 hours at RT.
  • TFA trifluoroacetic acid
  • Crude peptides are purified by preparative high pressure liquid chromatography (HPLC), for example using a Waters Delta-Pak C18 column and gradient elution with 0.1 % TFA in water modified with acetonitrile. After column elution, acetonitrile is evaporated from the eluted fractions, which are then lyophilized.
  • HPLC high pressure liquid chromatography
  • FABMS fast atom bombardment mass spectroscopy
  • ESMS electrospray mass spectroscopy
  • Various delivery systems for administering the combined therapy disclosed herein are known, and include e.g., encapsulation in liposomes. microparticles, microcapsules, expression by recombinant cells, receptor-mediated endocytosis (see Wu and Wu, /. Biol. Chem. 1987, 262:4429-32), and construction of a therapeutic nucleic acid as part of a retroviral or other vector.
  • Methods of introduction include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, and oral routes.
  • the compounds may be administered by any convenient route, for example by infusion or bolus injection, by abso ⁇ tion through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local.
  • the pharmaceutical compositions may be introduced into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. - 62 -
  • compositions disclosed herein may be desirable to administer the pharmaceutical compositions disclosed herein locally to the area in need of treatment, for example, by local infusion during surgery, topical application, e.g. , in conjunction with a wound dressing after surgery, by injection, through a catheter, by a suppository or an implant, such as a porous, non-porous, or gelatinous material, including membranes, such as silastic membranes, or fibers.
  • administration can be by direct injection at the site (or former site) of a malignant tumor or neoplastic or pre-neoplastic tissue.
  • liposomes as a delivery vehicle is one delivery method of interest.
  • the liposomes fuse with the target site and deliver the contents of the lumen intracellularly.
  • the liposomes are maintained in contact with the target cells for a sufficient time for fusion to occur, using various means to maintain contact, such as isolation and binding agents.
  • Liposomes may be prepared with purified proteins or peptides that mediate fusion of membranes, such as Sendai virus or influenza virus.
  • the lipids may be any useful combination of known liposome forming lipids, including cationic lipids, such as phosphatidylcholine.
  • lipids include neutral lipids, such as cholesterol, phosphatidyl serine, phosphatidyl glycerol, and the like.
  • neutral lipids such as cholesterol, phosphatidyl serine, phosphatidyl glycerol, and the like.
  • compositions which include a therapeutically effective amount of autologous CTLs specific to FGF-5 and/or an FGF-5 protein, RNA, DNA, antisense molecule or specific binding agent (for example, antibodies), alone or with a pharmaceutically acceptable carrier.
  • homogeneous compositions of the FGF-5 therapeutic molecules includes compositions that are comprised of at least 90% of the peptide, variant, analog, derivative or mimetic in the composition.
  • Such carriers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof.
  • the carrier and composition can be sterile, and the formulation suits the mode of administration.
  • the composition can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
  • the composition can be a liquid solution, suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder.
  • the composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides.
  • Oral formulations can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, and magnesium carbonate.
  • the amount of the therapeutic agent that will be effective in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined 63 -
  • in vitro assays may optionally be employed to help identify optimal dosage ranges.
  • the precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each subject's circumstances. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.
  • the disclosure also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions.
  • a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions.
  • Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
  • Instructions for use of the composition can also be included.
  • compositions or methods of treatment may be admmistered in combination with other therapeutic treatments, such as other antineoplastic or antitumorigenic therapies.
  • the analog is delivered intracellularly (e.g., by expression from a nucleic acid vector or by receptor- mediated mechanisms).
  • administration may be achieved by an appropriate nucleic acid expression vector which is administered so that it becomes intracellular, e.g., by use of a retroviral vector (see U.S. Patent No.
  • nucleic acid can be introduced intracellularly and inco ⁇ orated within a cell's cellular DNA for expression, by homologous recombination.
  • the vector pcDNA is an example of a method of introducing the foreign cDNA into a cell under the control of a strong viral promoter (CMV) to drive the expression.
  • CMV viral promoter
  • other vectors can be used (see EXAMPLES 8 and 14).
  • Other retroviral vectors such as pRETRO-ON, Clontech), also use this promoter but have the advantages of entering cells without any transfection aid, integrating into the genome of target cells only when the target cell is dividing (as cancer cells do, especially during first remissions after chemotherapy) and they are regulated. It is also possible to m on the expression of the FGF-5 nucleic acid by administering tetracycline when these 64 .
  • plasmids are used. Hence these plasmids can be allowed to transfect the cells, then administer a course of tetracycline with a course of chemotherapy to achieve better cytotoxicity.
  • plasmid vectors such as pMAM-neo (Clontech) or pMSG (Amersham Pharmacia Biotech) use the MMTV-LTR promoter (which can be regulated with steroids) or the SV10 late promoter (pSVL, Amersham Pharmacia Biotech) or metallothionein - responsive promoter (pBPV, Amersham Pharmacia Biotech) and other viral vectors, including retroviruses.
  • examples of other viral vectors include adenovirus, AAV (adeno-associated virus), recombinant HSV, poxviruses (vaccinia) and recombinant lentivirus (such as HIV). These vectors achieve the basic goal of delivering into the target cell the cDNA sequence and control elements needed for transcription.
  • the present disclosure includes all forms of nucleic acid delivery, including synthetic oligos, naked DNA, plasmid and viral, integrated into the genome or not.
  • the therapeutic molecule is an antibody, specifically an antibody that recognizes FGF-5 proteins
  • administration may be achieved by direct injection, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell- surface receptors or transfecting agents. Similar methods can be used to administer FGF-5 proteins, of fragments thereof.
  • compositions which include a therapeutically effective amount of the antibody, and a pharmaceutically acceptable carrier or excipient.
  • EXAMPLE 19 Antisense Disruption of FGF-5 Expression
  • This example describes methods that can be used to decrease FGF-5 expression. Such methods are useful when treatment of tumors which express or over-express FGF-5 is desired, for example in RCC and carcinoma of the breast, prostate, bladder or pancreas.
  • some subjects may not respond to modulation of the immune response by an agent having FGF-5 activity.
  • Such subjects may include non-HLA-A3 subjects.
  • subjects having an FGF-5 expressing or overexpressing neoplasm may respond to therapies which modulate FGF-5 expression or activity, for example by decreasing any neoplastic response to FGF- 5 expression, for example angiogenesis.
  • One approach to decreasing FGF-5 expression, activity, or function is to use antisense oligonucleotides.
  • the mRNA sequence from the desired molecule such as human FGF-5, is examined. Regions of the sequence containing multiple repeats, such as - 65
  • TTTTTTTTTT are not as desirable because they will lack specificity.
  • regions can be chosen. Of those, oligos are selected by the following characteristics: ones having the best conformation in solution; ones optimized for hybridization characteristics; and one having less potential to form secondary strucmres. Antisense molecules having a propensity to generate secondary strucmres are less desirable.
  • Plasmids containing FGF-5 antisense sequences can also be genereated. For example, cDNA fragments coding for human FGF-5 are PCR amplified. The nucleotides are then amplified using Pfu DNA polymerase (Stratagene) and cloned in antisense orientation a vector, such as pcDNA vectors (InVitrogen). The nucleotide sequence and orientation of the insert can be confirmed by dideoxy sequencing using a Sequenase kit (Amersham Pharmacia Biotech).
  • the term "antisense” refers to a nucleic acid capable of hybridizing to a portion of an FGF-5 RNA (such as mRNA) by virtue of some sequence complementarity.
  • the antisense nucleic acids disclosed herein can be oligonucleotides that are double-stranded or single-stranded, RNA or DNA or a modification or derivative thereof, which can be directly administered to a cell, or which can be produced intracellularly by transcription of exogenous, introduced sequences.
  • the FGF-5 antisense nucleic acids are polynucleotides, and may be oligonucleotides (ranging from 6 to about 100 oligonucleotides).
  • the oligonucleotide is at least 10, 15, 20, 62, 65, or 100 nucleotides, or a polynucleotide of at least 200 nucleotides.
  • the antisense nucleic acids may be much longer constructs.
  • the nucleotides can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded.
  • the nucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, and may include other appending groups such as peptides, or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al., Proc. Natl. Acad. Sci.
  • an FGF-5 antisense polynucleotide (including oligonucleotides) is provided, for example of single-stranded DNA.
  • the FGF-5 antisense polynucleotide may recognize any species of FGF-5.
  • the antisense polynucleotide may be modified at any position on its structure with substituents generally known in the art.
  • a modified base moiety may be 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5- carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta- D-galactosylqueosine, inosine, N ⁇ 6-sopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2- 66
  • the polynucleotide includes at least one modified sugar moiety such as arabinose, 2-fluoroarabinose, xylose, and hexose, or a modified component of the phosphate backbone, such as phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, or a formacetal or analog thereof.
  • modified sugar moiety such as arabinose, 2-fluoroarabinose, xylose, and hexose
  • a modified component of the phosphate backbone such as phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, or a formacetal or analog thereof.
  • the polynucleotide is an ⁇ -anomeric oligonucleotide.
  • An - anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual ⁇ -units, the strands run parallel to each other (Gautier et al., Nucl.
  • the oligonucleotide may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, or hybridization-triggered cleavage agent.
  • Oligonucleotides may include a targeting moiety that enhances uptake of the molecule by mmor cells.
  • the targeting moiety can be a specific binding molecule, such as an antibody or fragment thereof that recognizes a molecule present on the surface of a diseased cell, such as a mmor cell.
  • catalytic nucleic acid compounds such as ribozymes or anti-sense conjugates
  • Ribozymes may be synthesized and administered to the subject, or may be encoded on an expression vector, from which the ribozyme is synthesized in the targeted cell (as in PCT publication WO 9523225, and
  • oligonucleotides with catalytic activity are described in WO 9506764.
  • Conjugates of antisense with a metal complex, e.g. te ⁇ yridylCu (II), capable of mediating mRNA hydrolysis, are described in Bashkin et al. , 1995, Appl. Biochem Biotechnol. 54:43-56.
  • Polynucleotides disclosed herein can be synthesized by standard methods known in the art, for example by use of an automated DNA synthesizer (Biosearch, Applied Biosystems, etc.).
  • phosphorothioate oligos may be synthesized by the method of Stein et al. (Nucl. Acids Res. 1998, 16:3209), methylphosphonate oligos can be prepared by use of controlled pore glass polymer supports (Sarin et al., 1988, Proc. Natl. Acad. Sci. USA 85:7448-51).
  • the ILP-2 and ILP-3 antisense oligonucleotides comprise catalytic RNA, or a ⁇ 67 -
  • the oligonucleotide is a 2'-0-methylribonucleotide (Inoue et al., Nucl. Acids Res. 1987, 15:6131-48), or a chimeric RNA-DNA analogue (Inoue et al., FEBS Lett. 1987, 215:327-330).
  • the antisense polynucleic acids disclosed herein comprise a sequence complementary to at least a portion of an RNA transcript of an FGF-5 gene, such as a human FGF-5 gene. However, absolute complementarity, although advantageous, is not required.
  • a sequence can be complementary to at least a portion of an RNA, meaning a sequence having sufficient complementarily to be able to hybridize with the RNA, forming a stable duplex; in the case of double-strandedFGF-5antisense nucleic acids, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed.
  • the ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the longer the hybridizing nucleic acid, the more base mismatches with a FGF-5 RNA it may contain and still form a stable duplex (or triplex, as the case may be).
  • One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.
  • the relative ability of polynucleotides (such as oligonucleotides) to bind to complementary strands is compared by determining the melting temperature of a hybridization complex of the poly/oligonucleotide and its complementary strand.
  • Base stacking which occurs during hybridization, is accompanied by a reduction in UV abso ⁇ tion (hypochromicity).
  • a reduction in UV abso ⁇ tion indicates a higher T m .
  • the higher the T m the greater the strength of the binding of the hybridized strands.
  • As close to optimal fidelity of base pairing as possible achieves optimal hybridization of a poly/oligonucleotide to its target RNA.
  • compositions comprising FGF-5 antisense nucleic acids are administered via liposomes, microparticles, or microcapsules. In other embodiments, it may be useful to use such compositions to achieve sustained release of the FGF-5 antisense nucleic acids. In yet other embodiments, it may be desirable to utilize liposomes targeted via antibodies to specific identifiable tumor antigens
  • FGF-5 antisense oligonucleotides can be used to disrupt cellular expression of FGF-5 proteins, which results in a decrease in FGF-5 expression or activity, such as by a factor of at least 20% , 50% , or 80% .
  • the decrease in FGF-5 expression and/or activity may cause regression of FGF-5 expressing or non-expressing tumors.
  • the subject suffering from a disease in which FGF-5 is expressed or over-expressed can be treated with a therapeutically effective amount of FGF-5 antisense oligonucleotides. After the FGF-5 antisense has taken effect (FGF-5 levels are downregulated), for example after 24-48 hours, the subject can be monitored for regression of the mmor and/or lysis of the cells of the mmor.
  • the treatments disclosed herein can also be used prophylactially, for example to inhibit or prevent progression to of a disease in which FGF-5 is expressed or over-expressed. Such administration is indicated where the treatment is shown to have utility for treatment or prevention of the disorder.
  • the prophylactic use is indicated in conditions known or suspected of preceding progression to diseases associated with an undesired amount of FGF-5 expression. Such diseases may include tumors in which FGF-5 expression is elevated, such as RCC, breast cancer and prostate cancer.
  • fusion proteins Methods for making fusion proteins are well known to those skilled in the art.
  • U.S. Patent No. 6,057, 133 to Bauer et al. discloses methods for making fusion molecules composed of human interleukin-3 (hIL-3) variant or mutant proteins functionally joined to a second colony stimulating factor, cytokine, lymphokine, interleukin, hematopoietic growth factor or IL-3 variant.
  • U.S. Patent No. 6,072,041 to Davis et al. discloses the generation of fusion proteins comprising a single chain Fv molecule directed against a transcytotic receptor covalently linked to a therapeutic protein.
  • Linker 69 Similar methods can be used to generate fusion proteins comprising FGF-5 (or variants, mutants, polymo ⁇ hisms, or fragments thereof) linked to other amino acid sequences.
  • Linker 69
  • the linker region is generally a polypeptide of between 1 and 500 amino acids in length, for example less than 30 amino acid in length.
  • the linker joining the two molecules can be designed to (1) allow the two molecules to fold and act independently of each other, (2) not have a propensity for developing an ordered secondary structure which could interfere with the functional domains of the two proteins, (3) have minimal hydrophobic or charged characteristic which could interact with the functional protein domains and (4) provide steric separation of the two regions.
  • surface amino acids in flexible protein regions include Gly, Asn and Ser.
  • Other neutral amino acids, such as Thr and Ala can also be used in the linker sequence.
  • Additional amino acids may also be included in the linker due to the addition of unique restriction sites in the linker sequence to facilitate construction of the fusions.
  • Other moieties may also be included, as desired. These may include a binding region, such as avidin or an epitope, such as a polyhistadine tag, which may be useful for purification and processing of the fusion protein.
  • detectable markers can be attached to the fusion protein, so that the traffic of the fusion protein through a body or cell may be monitored conveniently. Such markers may include radionuclides, enzymes, fluors, and the like.
  • Fusing of the nucleic acid sequences of FGF-5 (or variants, mutants, polymo ⁇ hisms, or fragment thereof), with the nucleic acid sequence of another protein (or variants, mutants, polymo ⁇ hisms, or fragment thereof), can be accomplished by the use of intermediate vectors.
  • one gene can be cloned directly into a vector containing the other gene.
  • Linkers and adapters can be used for joining the nucleic acid sequences, as well as replacing lost sequences, where a restriction site was internal to the region of interest.
  • DNA Genetic material (DNA) encoding one polypeptide, peptide linker, and the other polypeptide is inserted into a suitable expression vector which is used to transform prokaryotic or eukaryotic cells, for example bacteria, yeast, insect cells or mammalian cells (see EXAMPLE 8).
  • a suitable expression vector which is used to transform prokaryotic or eukaryotic cells, for example bacteria, yeast, insect cells or mammalian cells (see EXAMPLE 8).
  • the transformed organism is grown and the protein isolated by standard techmques, for example by using a detectable marker such as nickel-chelate affinity chromatography, if a polyhistadine tag is used.
  • the resulting product is therefore a new protein, a fusion protein, which has FGF-5 joined by a linker region to a second protein.
  • the purified protein is subjected to electrophoresis in SDS-polyacrylamide gels, and transferred onto nitrocellulose membrane filters using established methods.
  • the protein products can be identified by Western blot analysis using antibodies directed against the individual components, i.e. , polyhistadine tag and FGF-5 (see EXAMPLE 9).
  • transgenic plants and animals which express FGF-5 can be made by techmques known in the art, for example those disclosed in U.S. Patent Nos. 5,574,206; 5,723,719; 5,175,383; 5,824,838; 5,811,633; 5,620,881; and 5,767,337, which are inco ⁇ orated by reference. Methods for generating transgenic mice are described in Gene Targeting, Joyuner ed., Oxford University Press, 1995 and Watson et al., Recombinant DNA 2nd Ed., W.H. Freeman and Co., New York, 1992, Chapter 14.
  • modulations in an immune response for example an increase or decrease in an immune response
  • the immune response can be determined by measuring IFN- ⁇ concentration, using the assays described in EXAMPLES 2 and 3.
  • concentration of IFN- ⁇ may increase by a desired amount, for example by at least 50%, at least 75% or even at least 1000%.
  • This immune response may reduced by a desired amount, for example by at least 50%, for example at least 75%, in the presence of pan-anti-class I MHC mAb (such as W6/32) or anti-HLA-A3 mAb (such as GAP A3).
  • pan-anti-class I MHC mAb such as W6/32
  • anti-HLA-A3 mAb such as GAP A3
  • the immune response can be modulated by increasing or decreasing the immune response.
  • FGF-5 or autologous CTLs specific to FGF-5 can be used provoke a CTL response against a mmor that is expressing or overexpressing FGF-5 in a subject to whom it is a ⁇ rninistered.
  • it is an amount of FGF-5 or autologous CTLs, specific to FGF-5, required to increase by more than a desired amount, for example by at least 50%, at least 75% or at least 1000% using the assay described in EXAMPLES 2 and 3.

Abstract

L'invention concerne des procédés pour traiter les tumeurs exprimant ou surexprimant le facteur de croissance des fibroblastes (FGF-5) de l'antigène associé aux tumeurs (TAA), y compris au carcinome des cellules rénales (RCC) et au carcinome de la prostate et du sein. Les procédés consistent à moduler une réponse immunitaire, par exemple, à augmenter une réponse immunitaire, ou à moduler l'expression ou l'activité de FGF-5. L'invention porte aussi sur des procédés pour déterminer une éventuelle susceptibilité d'un sujet vis-à-vis d'une maladie associée à l'expression anormale des FGF-5.
EP00968465A 1999-10-02 2000-09-29 Facteur de croissance des fibroblastes 5 (fgf-5) dans un antigene de leucocyte t associe aux tumeurs Withdrawn EP1225909A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15710399P 1999-10-02 1999-10-02
US157103P 1999-10-02
PCT/US2000/026689 WO2001025271A2 (fr) 1999-10-02 2000-09-29 Facteur de croissance des fibroblastes 5 (fgf-5) dans un antigene de leucocyte t associe aux tumeurs

Publications (1)

Publication Number Publication Date
EP1225909A2 true EP1225909A2 (fr) 2002-07-31

Family

ID=22562344

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00968465A Withdrawn EP1225909A2 (fr) 1999-10-02 2000-09-29 Facteur de croissance des fibroblastes 5 (fgf-5) dans un antigene de leucocyte t associe aux tumeurs

Country Status (5)

Country Link
EP (1) EP1225909A2 (fr)
JP (1) JP2003511388A (fr)
AU (1) AU774958B2 (fr)
CA (1) CA2384696A1 (fr)
WO (1) WO2001025271A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1562622A2 (fr) * 2002-11-19 2005-08-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Epitopes immunogenes pour facteur de croissance fibroplastique 5 (fgf-5) presente par hla-a3 et hla-a2
JP4934397B2 (ja) * 2006-10-19 2012-05-16 学校法人順天堂 トランスジェニック非ヒト動物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020125A1 (fr) * 1993-03-12 1994-09-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Traitement des affections des neurones moteurs a l'aide du facteur de croissance des fibroblastes 5 (fgf-5)
WO1995015176A1 (fr) * 1993-12-01 1995-06-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Procedes activant la duree de vie et facilitant la differentiation des sous-classes de neurones cholinergiques et serotonergiques a l'aide du facteur 5 de croissance des fibroblastes
WO1997030155A1 (fr) * 1996-02-15 1997-08-21 Chiron Corporation Methode de therapie genique au moyen de fgf-5
WO1999045952A2 (fr) * 1998-03-12 1999-09-16 Genentech, Inc. Methode de prevention de la mort des neurones de la retine et de traitement d'affections oculaires

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5063210A (en) * 1989-04-20 1991-11-05 Lange Iii Louis G Use of sulfated polysaccharides to decrease cholesterol and fatty acid absorption
US5191067A (en) * 1989-04-27 1993-03-02 The Salk Institute For Biological Studies Fibroblast growth factor conjugates
JP3472664B2 (ja) * 1996-06-28 2003-12-02 ポーラ化成工業株式会社 抗繊維芽細胞増殖因子５モノクローナル抗体
WO1999055861A2 (fr) * 1998-04-28 1999-11-04 Eisai Co., Ltd. Compositions de muteine du facteur de croissance de fibroblastes et procedes d'utilisation associes
AU4688499A (en) * 1998-10-23 2000-05-15 Human Genome Sciences, Inc. Fibroblast growth factor receptor-5

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020125A1 (fr) * 1993-03-12 1994-09-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Traitement des affections des neurones moteurs a l'aide du facteur de croissance des fibroblastes 5 (fgf-5)
WO1995015176A1 (fr) * 1993-12-01 1995-06-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Procedes activant la duree de vie et facilitant la differentiation des sous-classes de neurones cholinergiques et serotonergiques a l'aide du facteur 5 de croissance des fibroblastes
WO1997030155A1 (fr) * 1996-02-15 1997-08-21 Chiron Corporation Methode de therapie genique au moyen de fgf-5
WO1999045952A2 (fr) * 1998-03-12 1999-09-16 Genentech, Inc. Methode de prevention de la mort des neurones de la retine et de traitement d'affections oculaires

Also Published As

Publication number Publication date
JP2003511388A (ja) 2003-03-25
CA2384696A1 (fr) 2001-04-12
WO2001025271A2 (fr) 2001-04-12
WO2001025271A3 (fr) 2002-05-10
AU774958B2 (en) 2004-07-15
AU7837100A (en) 2001-05-10

Similar Documents

Publication Publication Date Title
US7141549B2 (en) Proteins and nucleic acids encoding same
US7276593B2 (en) Proteins and nucleic acids encoding same
US20060063200A1 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20040033491A1 (en) Proteins and nucleic acids encoding same
US20040029222A1 (en) Proteins and nucleic acids encoding same
US7109000B2 (en) Proteins and nucleic acids encoding same
US20080200391A1 (en) Human Extracellular Matrix-1
US20040010119A1 (en) Novel proteins and nucleic acids encoding same
US6989232B2 (en) Proteins and nucleic acids encoding same
US20080171046A1 (en) Novel proteins and nucleic acids encoding same
US6903201B2 (en) Proteins and nucleic acids encoding same
AU774958B2 (en) Fibroblast growth factor-5 (FGF-5) is a tumor associated T-cell antigen
CA2448540A1 (fr) Polypeptides therapeutiques, acides nucleiques codant ces polypeptides, et leurs procedes d'utilisation
US20030190715A1 (en) Novel proteins and nucleic acids encoding same
WO2000029578A9 (fr) Clonage et caractérisation de deux facteurs de transcription de l'arn messager
US20040029790A1 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
US20060084086A1 (en) Proteins, polynucleotides encoding them and methods of using the same
US20050042631A1 (en) Cloning and characterization of two novel m-RNA transcription factors
JP2001505433A (ja) ヒトｇタンパク質レセプターｈｃｅｇｈ４５，ｐａｃａｐ様（ｇタンパク質下垂体アデニル酸シクラーゼ活性化ポリペプチド様）受容体
US20040018977A1 (en) Semaphorin-like proteins and methods of using same
AU2003245387A1 (en) Semaphorin-like proteins and methods of using same
WO2001023568A2 (fr) Nouveaux membres de la famille du gene iap
US20030064489A1 (en) Novel polypeptides and nucleic acids encoding same
JP2005509400A (ja) タンパク質およびそれをコードする核酸
AU2002245121A1 (en) Proteins and nucleic acids encoding same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020425

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: YANG, JAMES, C.

Inventor name: HANADA, KEN-ICHI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110401